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Resistance to carbapenems, the ultimate beta-lactam antibiotics used to treat life-
threatening Gram-negative infections associates with very high mortality. 
Consequently, carbapenem resistant Enterobacteriaceae (CRE), which are usually 
multi- or extremely drug resistant, are considered a critical pathogen.  To help 
controlling their spread, we investigated the molecular epidemiology of CRE in the 
United Arab Emirates (UAE) and its neighboring countries. CRE isolated in the 
UAE were screened for IncX3 incompatibility type plasmids carrying 
carbapenemases. The complete sequence of the IncX3 plasmids identified was 
established. Thirty CRE carried blaNDM-1, blaNDM-4, blaNDM-5, blaNDM-7, blaOXA-181 and 
blaKPC-2 on IncX3 plasmids. These CRE belonged to 16 sequence types of five 
different species. Phylogenetic analysis of the conserved regions of local IncX3 
plasmids and of those described globally clustered them according to the 
carbapenemase genes carried, suggesting that they do not evolve locally, rather, are 
imported from other regions.  Furthermore, we investigated members of the 
Klebsiella pneumoniae ST14 clone, which was found to be significantly associated 
with NDM- and OXA-48-like double carbapenemase production, with extreme drug 
resistance, and with being isolated from Emirati patients in Dubai. To gain a deeper 
insight into the molecular features of this clone, 39 CRKP-ST14 selected from five 
cities of the UAE, from Bahrain and from Saudi Arabia were subjected to whole 
genome sequencing, and their resistome, virulome and core genome MLST was 
assessed. cgMLST revealed three clusters of 16 isolates from five UAE cities (C1), 
11 isolates from three UAE cities and Bahrain (C2) and the 5 isolates from Saudi 
Arabia (C3), respectively, and seven singletons. Resistance gene profile and 
carbapenemase carrying plasmid types were variable in both C1 and C2 clusters. 
Cluster 2 exhibited a capsular switch from K2 to K64. The successful dissemination 
of the CRKP-14 clone could be explained by the genetic flexibility demonstrated. 
Our data show that the emergence of CRE in the United Arab Emirates is a complex 






countrywide clonal transmission of a genetically flexible high-risk Klebsiella 
pneumoniae clone.  
Keywords: Enterobacteriaceae, carbapenem resistance, horizontal gene transfer, 






Title and Abstract (in Arabic) 
 
 في نيمالكاربابي مقاومة انتشار حالة في المعوية المكورات وبكتريا البالزميدات دور
المتحدة العربية اإلمارات دولة  
 الملخص
والتي تعتبر  Carbapenemsاصبحت مقاومة البكتيريا لمضادات الكاربابينيم 
 ،Gram Negativeالمضادات المثالية المستخدمة في عالج العدوى للبكتيريا سالبة الغرام 
 ولذلك، تعتبر بكتريا المكورات المعوية المقاومة للكاربابينيم ترتبط بمعدل وفيات مرتفع.
CRE،  للمساعدة في السيطرة و. لألمراضمسبب اساسي  لألدوية،والتي تكون مقاومة بشدة
قمنا بدراسة مستفيضة لهذه البكتيريا باستخدام علم األوبئة الجزيئي في دولة  انتشارها،على 
والتي تحتوي على  CRE تم فحص مجموعات من .اإلمارات العربية المتحدة والدول المجاورة
 IncX3 اتوالتسلسل الكامل لبالزميد carbapenemases الحامل لجينات ال IncX3 بالزميد
، blaNDM-1 ،blaNDM-4 ،blaNDM-5الحمل جينات  CRE وجدنا ثالثين
blaNDM-7 ،blaOXA-181و blaKPC-2  على بالزميداتIncX3 . وتنتمي مجموعات
التحليل النسجي للمناطق  .خمسة أنواع بكتيريةل  (ST)نوع تسلسلي  16إلى  CRE ال 
ً من حيث  IncX3 المحفوظة من بالزميدات المحلية ومقارنتها بتلك التي تم وصفها عالميا
بل يتم جلبها من  محليًا،التي تحملها، اشارت إلى أنها ال تتطور  carbapenemasesجينات ال 
 .مناطق أخرى
 Klebsiellaلقد قمنا ايضا بدراسة نوع معين من بكتيريا الكلبسية الرئوية
pneumoniae ST14،  والذي وجد أنه يرتبط بإنتاج ثنائي الcarbapenemases   NDM 
، مع مقاومة شديدة لألدوية، وقد تم عزل العينات من المرضى اإلماراتيين في OXA-48 و
عينة  93تم إخضاع  ،ST14وللحصول على نظرة أعمق للسمات الجزيئية ل .مستشفيات دبي
إلى فحص  السعودية،من البحرين ومن  ارات،اإلممن خمس مدن في من هذا النوع تم اختيارها 
. كشفت MLST و virulome وتم تقييم مقاومتها، النوع،تسلسلي كامل للجينوم الخاص بهذا 






(C1)،  الى البحرين باإلضافةعينة من ثالث مدن اماراتية  11والثانية من (C2)،  اما الثالثة
 .على التوالي وسبعة عينات فردية ،(C3) عينات من السعودية 5من  فتتكون
التي تحمل جينات ال  وانواع البالزميداتلقد كان التوصيف الجيني لمقاومة المضادات 
carbapenemase متغيرين في كال المجموعتين C1 وC2،  ولكن نوع الcapsular   K2 
-CRKPفي هذه المرونة الجينية .التوالي علىC2و C1 مرتبطان بشكل واضح مع كانا K64و
ST14  تشير بياناتنا إلى أن ظهور ال من سرعة انتشار هذا النوع. تعزز  قد CRE  في دولة
على نطاق  وإلى انتقالاإلمارات هو ظاهرة معقدة تتمثل في احتمال انتقال دولي للبالزميدات، 
ً  عالية Klebsiella pneumoniaeال لبكتيرياالدولة   .الخطورة والمرنة وراثيا
الجينات  نقل -carbapenem ال  مقاومة - المعويةبكتريا المكورات  :مفاهيم البحث الرئيسية
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Chapter 1: Introduction 
 
1.1 The international problem of antibiotic resistance 
With the discovery of the first antibiotics some hundred years ago, the danger 
of infectious diseases caused by bacteria diminished, or at least humanity perceived 
so. Unfortunately, antimicrobial agents, which used to have the ability to treat and 
prevent various infectious diseases are becoming less, or even completely un-
effective against different micro-organisms due to the occurrence of antibiotic 
resistance. As a consequence of the extensive use and often misuse of antibiotics for 
more than 70 years, different new mechanisms of antibiotic resistance arise in a 
dangerously high rate, and spread globally. As a result, without effective antibiotic 
agents available, we face difficulty in treating common and serious infectious 
diseases. Furthermore, in the near future, medical procedures requiring antibiotic 
prophylaxis, e.g. major surgical procedures or cancer chemotherapy, would be 
significantly compromised; leading to prolonged illness, disability and high mortality 
rates.  
The World Health Organization (WHO) has stated that antimicrobial 
resistance (AMR) is a “global health security threat that requires action across 
government sectors and society as a whole” [1]. The Centers for Disease Control and 
Prevention (CDC) has valued the excess direct healthcare costs associated with AMR 
to be as high as $20 billion, and extra costs to society for lost productivity as high as 





The resistance to antibiotics is a complex multifactorial process [3]. From the 
bacterial side it reflects evolution in action, due to continuous exposure to antibiotics, 
where selective pressure gives rise to the emergence of numerous resistance 
mechanisms [4]. This persistent evolution over the years has led to the emergence of 
multidrug resistant (MDR) and extremely drug resistant (XDR) strains. Historically, 
multidrug resistant organisms (MDROs) have affected patients in hospital settings, 
where exposure to antibiotics, frequent and/or long-term hospitalization, use of in-
dwelling devices, and host factors were the risks for acquisition [5, 6]. Over the last 
two decades, the difference between MDR healthcare-acquired and community-onset 
bacterial infections has become blurred, with a surge of antibiotic resistance genes 
located on mobile genetic elements (MGE), which spread efficiently between 
bacteria within  hosts in and out of hospitals [7]. This trend was observed in  
Enterobacteriaceae, a family of Gram-negative bacteria (GNB), which are especially 
important, as they are common cause of community-associated as well as healthcare-
associated infections [8]. Carbapenem resistant Enterobacteriaceae (CRE) are listed 
among the most urgent antibiotic resistance threats, both by the WHO and by the 
CDC [1, 2]. 
1.2 The Problem of CRE in the United Arab Emirates (UAE) 
As the only available antibiotic resistance surveillance data from the country 
(covering Abu Dhabi emirate only) revealed the UAE has seen the emergence of 
CRE in the past 8 years, especially in resistance to carbapenems in Klebsiella 
pneumoniae (K. pneumoniae), as percent of resistant isolates increased  from 0.5% in 






177). The situation is probably even worse in other parts of the country, as for 2017 
the CDDEP resistance map projects the level of carbapenem resistance in 
K.pneumoniae in the UAE between 10-16%.................................................................. 
(https://resistancemap.cddep.org/CountryPage.php?countryId=95&country=United+
Arab+Emirates).  Therefore, to potentially decrease transmission by helping infection 
control decisions, we investigated the modes of CRE spreading in the UAE, to 
explain whether this emergence is due to horizontal gene transfer or clonal spread. 
We studied the genetic background of carbapenemase genes, the plasmids carrying 
them, and the molecular features of a commonly encountered carbapenem resistant 
clone of K. pneumoniae by whole genome sequencing (WGS). 
1.3 Enterobacteriaceae 
 The family of Enterobacteriaceae belongs to the order of Enterobacteriales, 
which is a large diverse group of rod shape Gram negative, facultative anaerobic 
bacteria [9]. Enterobacteriaceae encloses several genera such as Escherichia [10],  
Citrobacter [11], Enterobacter [12], Klebsiella [13], Salmonella [14], Shigella [15].  
All genera in this group are catalase-positive and oxidase-negative. 
Enterobacteriaceae are ubiquitous organisms, these organisms are inhabitants of the 
intestinal flora of most animals, including man, and can be found also in water, soil 
and plants [16, 17]. 
1.3.1 Klebsiella pneumoniae as a human pathogen  
Klebsiella pneumoniae is a significant member of the Klebsiella genus that 





lactose-fermenting, rod-shaped bacillus with a prominent capsule. K. pneumoniae 
has a ubiquitous distribution among animals, humans, plants, soil and both salt and 
fresh water environments [18]. K. pneumoniae is a natural inhabitant of the normal 
microbiota of the animal gut, whereas rate of colonization in healthy human has been 
reported to be around 6 % [19, 20], while the rate was higher in cows reaching ~44% 
[21]; K. pneumoniae has also been recovered and cultured from other domestic and 
agriculture animals, earthworms, insects and even  fish and shellfish [22].  
After Escherichia coli (E. coli), K. pneumoniae is the most reported Gram 
negative pathogen causing a wide range of human infections [23], it has been 
considered as an opportunistic pathogen, since it affects patients with compromised 
immune system or those who are debilitated by other infections [18]; these 
opportunistic K. pneumoniae are the causative agents of multiple infections in 
humans, including pneumonia, urinary tract infections (UTI), surgical wound 
infections and even more severe, life-threatening infections such as bloodstream 
infection and endocarditis [24, 25]. 
Klebsiella species have been reported as one of the leading cause of 
nosocomial infections, or hospital acquired infections (HAIs) [25, 26]. These 
infections caused by K. pneumoniae tend to be critical for two main reasons: first, K. 
pneumoniae biofilms created in vivo guard the pathogen from attacks of the host 
immune responses and antibiotics [27, 28]; second, nosocomial isolates of K. 
pneumoniae are often multidrug-resistant, thus it is challenging to find suitable 





Moreover, K. pneumoniae is reported as the second leading cause of 
bloodstream infection (BSI) right after E. coli [25]. BSI occurs often as a secondary 
infection due to dissemination from a known source into the bloodstream, e.g. from 
the gastrointestinal tract, respiratory sites, the urinary tract or from an intravenous or 
urinary catheter [31]. 
Currently, two forms of K. pneumoniae strains are evolving: The classical K. 
pneumoniae, which is often multidrug resistant (MDR-KP) or even carbapenem-
resistant (CRKP) causing opportunistic, frequently HAIs; and the other form is the 
hypervirulent K. pneumoniae (hvKP). The hvKP is highly invasive and usually 
affects previously healthy people causing life-threatening invasive infections often 
acquired in the community, e.g. meningitis, severe pneumonia, endophthalmitis, 
necrotizing skin and soft tissue infections (NSSTI) and pyogenic liver abscess [32, 
33]. HvKP infections are now being extensively reported around the Globe [34-39]. 
CRKP strains and hvKP types rarely overlap; CRKP is mostly of low virulence and 
not frequently linked to invasive infections [40]. However, few cases have been 
reported where CRKP caused NSSTI in liver transplant patients [41]. Recently, the 
emergence of hypervirulent CRKP (hv-CRKP) was reported mostly from Asia [42-
44], and lately, a hv-CRKP causing NSSTI was reported from USA as well [45]. 
Numerous factors ameliorate K. pneumoniae virulence, such as its ability to 
produce siderophores (scavenge essential iron), lipopolysaccharide (provide serum 
resistance) and extracellular polysaccharide capsule (for evasion and inhibition of 
phagocytosis) [18];  The striking ability of hvKP strains to cause severe infections is 





overproduction of capsular polysaccharide [46]. Genes encoding the synthesis of 
capsules in K. pneumoniae are located on the capsular polysaccharide synthesis locus 
(cps). Expression of the cps genes and hypermucoviscous phenotype has been 
reported to be associated and regulated by various proteins among which are the 
RmpA and RmpA2 proteins; those proteins are reported to be highly associated with 
HvKP especially in Asia [47].     
The biochemical characteristics and complexity of the capsule leads to the 
creation of strain specific antigenic types of the capsular material. So far, 78 capsular 
serotypes (K antigen) have been recognized in K. pneumoniae, those antigens have 
been used to differentiate between strains during clinical infections [48-50]. 
However, only a small subset of hvKP serotypes (mostly K1 and K2) have a 
distinctive hypermucoviscous phenotype, due to the increased production of capsular 
polysaccharide, which is considered to be one of the most important virulence factor 
of K. pneumoniae [32, 33, 51].  
Siderophores, another important virulence factor secreted by wide variety of 
bacteria including K.pneumoniae, are high affinity iron chelating molecules; they aid 
in iron acquisition since iron is vital for bacterial replication and growth, and plays a 
crucial role in the establishment of infection [52]. K. pneumoniae may encode a 
number of siderophores, such as aerobactin, yersiniabactin, enterobactin and 
salmochelin; expression and influence of each siderophore to virulence differ, as well 
as, their affinity to iron, with aerobactin having the lowest affinity while enterobactin 
having the highest [46]. Yersiniabactin (Ybt), which was first detected in Yersinia 





isolates, playing a crucial role in pathogenesis [53]. ICEkp which is an integrative 
conjugative element, is responsible for the mobilization of ybt locus in 
K.pneumoniae, it encodes genes essential for the regulation, biosynthesis and 
transport of yersinibactin siderophore and its receptors [54, 55].  
1.4 Mechanism of action of antibiotics 
The mechanisms of action by which antimicrobial agents inhibit the growth 
or cause bacterial death are diverse, and depend on the targets affected; for example, 
antibiotics can interfere with microbial metabolism either by affecting the plasma 
membrane integrity or by inhibiting cell wall synthesis, nucleic acid synthesis, 
protein synthesis or folate synthesis.  
Anti-Gram-negative antimicrobial agents belong to several classes of 
antibiotics: beta-lactam (β-lactam) antibiotics, including penicillin and derivatives, 
cephalosporins, monobactams and carbapenems, which inhibit peptidoglycan 
synthesis. Polymyxin B and polymyxin E (colistin) cause cell leakage by disrupting 
the bacterial outer membrane. Quinolones inhibit DNA replication by binding to 
bacterial complex of DNA-DNA topoisomerase II and IV. Rifampin, on the other 
hand, bind to DNA directed RNA polymerase thus blocks RNA synthesis. Some 
other antibiotics such as aminoglycosides, chloramphenicol and tetracycline all 
interfere with ribosome function and block protein synthesis. Sulfonamides and 





1.5 Mechanisms of acquired bacterial resistance to antibiotics  
Bacterial resistance can be either natural or acquired. Acquired resistance 
may develop by mutations, which lead to modification of the target molecule of the 
antibiotic, thus reduces the antibiotic affinity to its target. Mutations in permeability 
channel proteins or their expression lead to reduction in the porin production. 
Mutations can also increase expression of efflux pump systems that also leads to 
decreased concentration of antibiotics at the target site. Furthermore, mutations can 
also change the substrate spectrum of degrading enzymes that render the antibiotic 
less active or inactive [57]. 
Generally, bacteria overcome the inhibitory action of antibiotics by three 
primary mechanisms that frequently operate simultaneously with each other. These 
mechanisms are:  decrease in the uptake of the drug [58, 59], inactivation of the drug 
[60] and target modification [61]. Bacterial resistance develops either by spontaneous 
mutations in existing genes, or by the acquisition of  genes encoding new degrading 
enzymes, or a molecule protecting the target, or a new efflux pump [56]. The 
survival of resistant mutants is a matter of cost of fitness in a given environment [62, 
63].  
1.6 Antimicrobial resistance mechanisms of bacteria 
1.6.1 Decreased uptake of antibiotics  
Antibiotics should penetrate the outer membrane (OM) of bacteria in order to 
reach their targets and exert their effect.  The OM of Gram-negative bacteria is 
comprised of a lipopolysaccharide-phospholipid bilayer and of porins [64] . Bacteria 





absorption of these molecules or increasing their discharge, or by using both 
mechanisms together.  
In theory, hydrophilic antibiotics, such as beta-lactams, pass through porins, 
while hydrophobic antibiotics, as quinolones and macrolides, pass through the lipid 
bilayer [64, 65].  
The OM porins of bacteria may be modified via the substitution of only one 
or two amino acids to act as a permeability barrier for antibiotics. This, in addition to 
upregulation of efflux molecules may work together significantly increasing the 
discharge of antibiotics, thus avoiding accumulation on target [59]. During the 
1970s, detection of efflux-mediated resistance against tetracycline was first 
discovered among E. coli isolates [66, 67]. Since then various structures functioning 
as efflux pumps have been reported. Efflux pumps are recognized as one of the main 
mechanisms of MDR in bacteria, mostly among Gram-negative bacteria [68, 69]. 
The substrate specificity of efflux pumps widely differs, and some of them were 
found to have an extraordinarily broad spectrum [68].  
1.6.2 Target modification and protection 
In order for the bacteria to avoid the harmful effect of antibiotics, it modifies 
or even replaces target molecules [70]. In the 1960s, methicillin resistance among 
Staphylococcus aureus (MRSA) was first observed, which emerged through the 
replacement of the target molecule [71]. β-lactam antibiotics act on the cell wall 
synthesis, and inactivate penicillin binding proteins (PBPs) initiating dysregulation 
of the  peptidoglycan synthesis, and activating a series of events that eventually lead 





reduced affinity to beta-lactam antibiotics. PBP-2a is fully active, and able to restore 
the vital functions of inactivated PBPs [73].  
Plasmid-mediated quinolone resistance (PMQR) is a prominent example of 
target protection. Several unique oligopeptides encoded on genes known as “qnr”, 
are capable of protecting gyrase from the inhibition by quinolones [74]. These 
proteins primarily spread on multi-resistance plasmids, mostly along with extended-
spectrum beta-lactamases (ESBLs) or carbapenemases [75].  
Another form of modification, which cause an extreme level of resistance to 
aminoglycoside (AG), is achieved by the modification of AG binding site 
enzymatically (methylation of bacterial 16S rRNA) by 16S ribosomal RNA 
methyltransferases (RMTase) [76, 77]. So far, 10 types of 16S rRNA methylases 
have been reported from clinical isolates, these are  ArmA, RmtA, RmtB, RmtC, 
RmtD, RmtE, RmtF, RmtG, RmtH and NpmA [78-80]. The first reported 16S rRNA 
methylase gene armA was located on a plasmid from a clinical K. pneumoniae strain 
in France [81]. Sequencing of the genetic surrounding of armA showed that this gene 
is mostly located on a transposon giving it a great advantage in dissemination [81, 
82]. 
Polymyxin resistance is acquired by altering the lipid A component of the 
OM via spontaneous mutations [83]. Lately, plasmid mediated colistin resistance due 
to lipid A modifying enzymes (mcr-1 to -8) has been reported to insidiously 





Resistance to sulfonamides and trimethoprim in Gram negatives is mainly 
due to plasmid mediated sul and dfr genes, which are encoding nonallelic and drug-
resistant variants of the chromosomal target enzymes dihydropteroate synthase and 
dihydrofolate reductase. Therefore, acquisition of these renders bacteria resistant to 
folate pathway inhibitors [86]. 
1.6.3 Enzymatic inactivation of antibiotics  
Aminoglycosides resistance emerged between numerous species of bacteria, 
predominantly among Gram-negatives, Gram-positives, and Mycobacterium, due to 
the dissemination of aminoglycoside-modifying enzymes (AMEs) carried on mobile 
genetic elements [87]. AMEs resemble the rRNA targets of aminoglycosides, thus 
have the ability to bind to aminoglycosides instead of the target molecule and 
inactivate them [88]. Beta-lactamase (β-lactamase) mediated resistance is another 
form of bacterial resistance by enzymatic inactivation of antibiotics. 
1.6.3.1 Beta-lactam resistance genes 
Beta-lactam antibiotics are natural products of some microorganisms. Thus, 
in nature, even before the human history, microorganisms produced beta-lactamases 
and survived in the presence of antibiotic producers [89].  
Since 1940s, β-lactam antibiotics were used and prescribed in human 
medicine, and they are considered as a major, probably the most important class of 
antibacterial agents.  Subsequently, after their introduction, various β-lactamases 
have been produced by enteric pathogens, including K. pneumoniae, reaching an 





Two main schemes are employed to categorize β-lactamases; the first scheme 
is based on molecular discrimination (proposed by Ambler) depending on amino acid 
sequences and functional differences. The other scheme suggested by Bush-Jacoby-
Medeiros divides enzymes according to their substrate and inhibitor specificities 
[91]. The Ambler scheme is more commonly used, with each β-lactamase class 
grouping proteins according to apparent features, such as conserved amino acid 
motifs or molecular weight [92]. 
Due to the extremely large number and variety of beta-lactamases, in the 
following paragraphs mainly beta-lactamases produced by K. pneumoniae, i.e. the 
subject of my thesis, will be discussed. 
1.6.3.1.1 Broad-spectrum and extended-spectrum β-lactamases  
The first described β-lactamase gene, blaTEM-1 (named after Temoniera) was 
discovered in E. coli in 1963 in Greece [93]. This enzyme had a narrow hydrolytic 
profile compared to the extended-spectrum β-lactamase (ESBL) enzymes discussed 
below, although blaTEM-1, similarly to the majority of ESBLs, belong to the Ambler 
class A of beta-lactamases. 
Twenty years later, in 1985, the first extended spectrum β-lactamase (ESBL) 
gene, blaSHV-2, was identified in a clinical isolate of K. pneumoniae in Germany [94]. 
This β-lactamase gene showed an extended-spectrum activity against penicillin 
derivatives, as well as against third-generation cephalosporins and monobactams. 
Soon after, blaTEM-3, a new plasmid-mediated ESBL variant was described from this 





Since the occurrence of ESBL in K. pneumoniae, this pathogen has become 
the major ESBL-carrying pathogen related to nosocomial outbreaks [96, 97]. 
Moreover, occurrences of K. pneumoniae strains in different countries harboring 
various alleles of TEM and SHV β-lactamases were reported throughout 1990-2000s 
[98, 99]. 
Later in the 2000s, identification of plasmids and transposons encoding 
blaCTX-M-type ESBLs lead to a shift in the type of ESBLs present in K. pneumoniae 
associated with hospital outbreaks, and since then we experience the dominance of 
CTX-M producing strains [100]. 
Combination therapy with beta-lactams and classical β-lactamase inhibitors 
(e.g. clavulanic acid, sulbactam and tazobactam) (BL+BLI) is a successful strategy to 
overcome non-ESBL TEM-type mediated resistance. However, it was reported that 
the susceptibility of some Enterobacteriacea isolates to β-lactamase inhibitors can be 
altered by the modification of the outer membrane proteins or by the 
hyperproduction of unmodified TEM-type β-lactamase [101, 102], or by both 
mechanisms [103]. Resistance to BLI may also be owed to production of OXA-type 
enzymes, or to high level production of a cephalosporinase [104].  
Since 1990, the effect of β-lactamase inhibitors has been compromised by the 
occurrence of mutant TEM-type β-lactamases [105, 106], termed as inhibitor-
resistant TEM or IRT β-lactamases, these are enzymes that are only partially 





The prevalence of ESBL producing K. pneumoniae is increasing worldwide, 
being epidemic in many countries [100], although the exact figures and ESBL gene 
content differ between different geographical regions. According to the WHO, the 
prevalence of ESBL-producing K. pneumoniae has reached now endemic rates of up 
to 50% in many parts of the world, and up to 30% in the community indicating the 
expansive nature of this resistance [1]. 
1.6.3.1.2 Plasmid-mediated AmpC genes (pAmpC) 
During the late 1980s and early 1990s, blaAmpC gene families have emerged. 
They are also serine beta-lactamases, but members of the Ambler class C. The most 
abundant blaAmpC gene families in K. pneumoniae belong to the CMY, DHA, FOX 
and MOX types. Plasmid-encoded blaACT, blaMIR, blaACC and blaLAT appear to be 
very rare AmpC genes in this species [107].  
In parallel with the explosion of ESBL genes, emergence and spread of 
plasmid-mediated AmpC-like cephalosporinases in K. pneumoniae was reported, 
[107, 108] and they were entirely plasmid-born in this species [107]. Nevertheless, as 
a manifest to the species evolutionary propensity to integrate resistant genes into its 
chromosome, the first chromosomal AmpC, blaCMY-2 was identified in K. 
pneumoniae in 2015 [109]. Acquisition of AmpC enzymes combined with porin loss 
or increased efflux resulted in enhanced resistance to β-lactams in K. pneumoniae. 
These genes can be overexpressed on plasmids due to high copy number, or 






1.6.3.1.3 Carbapenem resistance  
Carbapenems are antimicrobial agents which are extremely stable to 
degradation by ESBLs and pAmpC, thus used to treat severe infections caused by 
ESBLs and pAmpC producers [110]. However, the MDR phenotype characteristics 
of these ESBL-producing K. pneumoniae strains have led to a remarkable increase in 
carbapenem use, which was the last resort to treat ESBL producing K. pneumoniae 
[111]. As a result of such extensive use of carbapenems, emergence of plasmid-
mediated carbapenemases occurred with the ability to hydrolyze all β-lactams 
including the last-line carbapenems [112].  
In 1988, the first plasmid-coded carbapenemase, IMI-1, was described in a 
Japanese Pseudomonas aeruginosa (P. aeruginosa) isolate [113]. The first 
carbapenemase produced by Enterobacteriaceae, NmcA was identified in a clinical 
isolate of Enterobacter cloacae in 1993  [114].  
Their appearance in Enterobacteriaceae led to carbapenem resistant 
Enterobacteriaceae (CRE). Klebsiella turned out to be the major CRE to have spread 
worldwide, probably due to its hospital association [115], posing a frequent 
therapeutic challenge and a major public health threat [116].  
CRKP strains are now relatively common and because patients infected with 
these strains frequently receive inadequate empiric and definitive antibiotic therapy, 





A. Mechanisms of resistance to carbapenems in Enterobacteriaceae 
Carbapenem resistance was first noted in Enterobacteriaceae due to 
overproduction of AmpC β-lactamases or ESBLs associated with permeability 
alterations due to porin loss and/or over expression of efflux pumps [119, 120].  
The carbapenemase genes in Enterobacteriaceae have been shown to be 
associated with mobile genetic elements such as plasmids or transposons, thereby 
facilitating their dissemination into the community and the environment [112].  
While these plasmid-encoded carbapenemases have been increasingly reported 
worldwide, their prevalence varies geographically [121, 122]. 
Among the four classes of β-lactamases defined by the Ambler classification 
system, the carbapenemases belong to three [112, 123]: the Ambler class A (serine 
carbapenemases), class B (metallo‐β‐lactamases), and class D, i.e. OXA-type β-
lactamases [112]. Furthermore, rare chromosomally encoded cephalosporinases 
(Ambler class C) produced by Enterobacteriaceae may possess minor extended 
activity toward carbapenems [112, 124]. 
I. Class A carbapenemases 
Class A β-lactamases includes: Klebsiella pneumoniae carbapenemase 
(KPC), Non–metallo-carbapenemase-A (NmcA), imipenemase (IMI), Serratia 
marcescens enzyme (SME), Serratia fonticola carbapenemase (SFC) and Guiana 
extended spectrum β-lactamases (GES); these enzymes are inhibited in vitro by 
clavulanic acid or boronic acid [112]. 





distribution of all carbapenemases associated with Enterobacteriaceae. In 1996, the 
first KPC- producing K. pneumoniae was isolated from a patient in North Carolina in 
the United States of America (USA) [125]. blaKPC genes are generally encoded on 
plasmid and has been extensively described in K. pneumoniae [30]; these enzymes 
provide resistance to penicillins, cephamycins, cephalosporins, carbapenems and 
monobactams and can be weakly inhibited by classical β-lactamase inhibitors such as 
tazobactam or clavulanic acid [112]. Moreover, strains harboring blaKPC often have 
acquired resistance to fluoroquinolones, aminoglycosides, and trimethoprim-
sulfamethoxazole, creating MDROs [126]. As a consequence, increased mortality 
rates were shown for infections caused by KPC-producing K. pneumoniae [30]. 
Although, more than 22 different variants of KPC have been reported [127], KPC-2 
and KPC-3 are the most commonly identified variants [128], and these latter are the 
highly prevalent ones in strains involved in hospital outbreaks in many countries 
[129]. 
 The main force for international dissemination of these genes was, and still is 
clonal expansion of K. pneumoniae of sequence type 258 (ST258), which, since its 
first description has become endemic in many countries around the world [30, 130-
132]. Further to clonal spread, blaKPC genes mostly reside in distinctive Tn4401 
transposon variants [133-135], and can be inserted into plasmids of various replicon 
types, which eases the dissemination of the gene to other bacterial species [136-138]. 
In addition to the K. pneumoniae ST258, several sequence types harboring blaKPC on 





As stated earlier, the first KPC-producing K. pneumoniae was reported from 
USA in 1996 [125]. By 2001, there was a tremendous escalation of KPC-producing 
bacteria in hospitalized patients in the North-Eastern United States [30, 141]. The 
increasing prevalence and extensive geographical spread of KPC-producing bacteria 
across the USA is obvious: as of April 2016, the CDC stated that KPC producing 
bacteria have been recognized in 48 member states. Nevertheless, the endemicity of 
KPC producing bacteria is still focused in regional hot spots within the USA [142, 
143]. Outbreaks of KPC-2-producing K. pneumoniae were caused by several K. 
pneumoniae clones including ST37, ST392, ST395 and ST11, suggesting the 
horizontal transfer of  blaKPC-2 gene between different K. pneumoniae clones [144].  
Apart from North America, KPC-producing CRE are also prevalent in South 
and Central America, where KPC-producing bacteria spread throughout Colombia 
after the discovery of K. pneumoniae harboring blaKPC-2 in patients with no travel 
history [145-147]. In Colombia, an outbreak of K. pneumoniae carrying blaKPC-3 was 
also recorded, which when traced back, was linked to a patient who had a prior travel 
to Israel [147, 148]. 
In Latin America, outside of Colombia, the highest occurrence of blaKPC 
carrying bacteria is in Brazil, with reports of KPC-producing isolates spreading in all 
states [149]. The dissemination in Brazil has been linked mostly to clonal complex 
258 (CC258) K. pneumoniae, containing ST258, ST11 and ST437; these strains 
bearing a blaKPC-2 gene located in Tn4401b transposon and in multiple plasmids types 





In Europe, the highest occurrence of KPC-producing Enterobacteriaceae is in 
the Mediterranean countries, specifically in Greece and Italy [152]. These were the 
only two European countries reported to have an “endemic situation” for KPC in 
2014–2015 [152]. Although other carbapenemases are present in Greece and Italy, 
KPC remains the most common reason of carbapenem resistance [152].  
In the Middle East, a significant epidemic of KPC-producing 
Enterobacteriaceae has evolved in Israel, which was the second country (after USA) 
to report outbreaks of infection due to KPC-producing K. pneumoniae. During 2004–
2006 a study of CRKP revealed epidemic blaKPC-2 or blaKPC-3 carrying strains. 
However, the peak of the outbreak was in 2007 [153, 154]. Although other 
carbapenemase genes were also reported in 2008 (including blaNDM and blaOXA-48-
like), KPC producing K. pneumoniae remained the predominant CRE, with an 
increasing proportion of ST258 K. pneumoniae strains [155]. In the Arabian 
Peninsula, the occurrence of KPC-producing K. pneumoniae is low compared to 
other carbapenemases [156]. The first documented KPC-producer K. pneumoniae 
were two K. pneumoniae ST14 strains harboring blaKPC-2 in the United Arab 
Emirates (UAE) in 2015 [157]. 
II. Class B Metallo-β-Lactamases 
Metallo-β-lactamases (MβLs, Ambler class B) are zinc dependent enzymes. 
These metal ions attract water molecules that render them nucleophiles, thus 
hydrolyze the cyclic amide bond of the β-lactam ring, rendering the β-lactam 
biologically inactive [158, 159]. The clinically important MBL types in K. 





(active-on-imipenem), and Verona integron–encoded metallo-β-lactamase (VIM) 
type enzymes [159, 161].  
MBLs genes are a complex group of enzymes hydrolyzing all β -lactams with 
the exception of aztreonam [162]. Their activity is inhibited in vitro by EDTA and 
dipicolinic acid, but not by any commercially available β-lactamase inhibitors such 
as clavulanic acid [160, 163, 164]. The spread of MBLs herald the emergence of pan-
resistant bacteria and considered as an imminent health-care crises worldwide [165]. 
In 1993, the first transmissible carbapenemase gene, blaIMP-1 was identified in 
a clinical Serratia marcescens isolate in Japan; this MBL gene was found on an 
integron and was associated with a plasmid-mediated outbreak. Extensive spread of 
blaIMP-1 harboring Enterobacteriaceae all over Japan followed this event [166]. 
So far, at least 52 variants of IMP genes have been identified in various 
species from different regions around the world; however, IMP type MBL-containing 
Enterobacteriaceae are endemic only in Taiwan and Japan [167]. Reports from 
Europe and other countries showed mostly sporadic outbreaks or single occurrence 
of IMP-type MBLs [90, 115, 139].  
In 1996 and 1997, VIM-type MBLs were identified in P. aeruginosa from 
Verona, Italy (VIM-1), and France (VIM-2) [168, 169]. After its initial discovery, 
bacteria producing VIM enzymes have been identified globally [167]. VIM-
producing Enterobacteriaceae are commonly reported from K. pneumoniae, E. coli 
and Enterobacter species [112, 117, 160]. So far, at least 46 blaVIM variants have 





integrons that facilitate their inter species dissemination [129]. 
In Spain, Italy and Hungary, “inter-regional spread” of VIM producers has 
been reported [152]. Emergence of multidrug-resistant K. pneumoniae isolates 
producing VIM-4 metallo-beta-lactamase was reported in 2005 in 11 patients from 
Tunisia [170]. VIM-producing CRE was reported as well from Nigeria and South 
Africa [171]. A plasmid-mediated outbreak of VIM-4 producer Enterobacteriaceae 
was reported from Kuwait [172], where otherwise only sporadic occurrence of VIM-
producer Enterobacteriaceae was reported earlier [173]. 
In 2009, MBL-producing Enterobacteriaceae became the center of attention, 
as K. pneumoniae ST14 with a new MBL gene, New-Delhi-metallo-beta-lactamase 
(blaNDM-1) was identified from a Swedish patient who received healthcare in New 
Delhi, India [174]. Subsequently, there has been an international dissemination of 
NDM-type MBLs with rapid gene transfer between species. Twenty variants of 
NDM enzyme have been described so far, most of them originated in Asia [175-177].  
Most of NDM producing bacteria also carry a diversity of other resistance 
mechanisms [167]. These extra mechanisms include the following: plasmid-mediated 
AmpC β-lactamases (especially CMY types), ESBLs (especially CTX-M-15), 
different carbapenemases (e.g., OXA-48, VIM, and KPC types), 16S rRNA 
methyltransferases, PMQR determinants, macrolide-modifying esterases, and 
rifampin-modifying enzymes. Consequently, most of Enterobacteriaceae with 
NDM-type enzymes remain susceptible to colistin, fosfomycin, and tigecycline, only 





Despite the resemblance between the high rate of spread of NDM-producing 
Enterobacteriaceae and that of KPC-producing Enterobacteriaceae, the 
dissemination of NDM-type MBLs does not appear to be related to a specific 
dominating clone; rather it is facilitated by dissemination of plasmids of various 
incompatibility (Inc) types [180, 181]. Nevertheless, NDM-type MBL genes have 
been reported in some epidemic clones, including K. pneumoniae  ST147 and ST11 
and E. coli ST101 and ST131, which are well-known to carry other β-lactamase 
genes and antibiotic resistance determinants [139, 182, 183]. 
In Europe, NDM producers have been commonly identified in Poland, 
Denmark, and Romania where “inter-regional spread” is thought to be present [152]. 
Although the MBL production as a reason of carbapenem resistance remained 
uncommon in Enterobacteriaceae isolates of the USA and Canada [184], in 2012 an 
outbreak of blaNDM-1 producing K. pneumoniae was reported from Denver [185].  
Later, in 2016, 157 NDM-producing CRE were reported from 25 states to the CDC 
[143]. 
On the other hand, several outbreaks were reported from South Africa, raising 
concerns that NDM-producing CRE are moving towards endemicity [186, 187]. 
Furthermore, NDM-producing CRE have been described from other African 






In the Middle East, NDM-producing Enterobacteriaceae are endemic, and 
this enzyme is one of the most frequent cause of carbapenem resistance in this family 
of bacteria [156, 194, 195]. 
III. OXA-48-like Class D carbapenemases 
Class D β-lactamases (oxacillinases) are enzymes that powerfully hydrolyze 
narrow-spectrum β–lactams, weakly or not hydrolyze cephalosporins, and are not 
inhibited by classical inhibitors. The OXA-48-like subgroups of this enzyme family 
also hydrolyze, albeit weakly, carbapenems [167, 196, 197]. If isolates producing 
these enzymes also produce an ESBL enzyme and/or have a permeability defect, they 
may be resistant to all β-lactam antibiotics [198].  
CRE-producing OXA-48-like enzymes may be hard to recognize [122], 
because of the heterogeneity of hydrolysis of carbapenems, broad-spectrum 
cephalosporins, aztreonam and absence of inhibition by EDTA or clavulanic acid, 
thus the prevalence of these enzymes is most likely underestimated [167, 199]. 
The first OXA-48 producer was isolated from K. pneumoniae strain, from a 
54-year-old man with a urinary tract infection and skin burns from Istanbul, Turkey 
in 2001 [200]. Since then OXA-48-like producing K. pneumoniae clones have 
persisted as a source of nosocomial infection reaching the highest epidemiologic 
level in Turkey [201-204]. Nevertheless, OXA-48-like and its variants became 
clinically significant worldwide [121]. It has been described in all members of the 
Enterobacteriaceae family; however, it is mostly found in isolates of E. coli of 





Among carbapenems, OXA-48 has a weak hydrolytic activity for both 
imipenem and meropenem compared to ertapenem, which is considered the best 
substrate for this enzyme [205].  
Several variants have emerged that differs from OXA-48 by one to five 
amino acid substitutions and/or by a four-amino- acid deletion, which lead to a 
modification in the β-lactam hydrolysis spectrum [198, 200, 206]. These include 
OXA-162 (single replacement at Thr213Ala) described in Turkey from K. 
pneumoniae isolates [207]; OXA-181 (four substitutions at Thr104Ala, Asn110Asp, 
Glu168Gln, and Ser171Ala) emerged in a K. pneumoniae isolate from India [208]; 
OXA-163 (with single substitution at Ser212Asp and four deletions at Arg214, 
Ile215, Glu216, and Pro217) which was collected from Enterobacter cloacae and K. 
pneumoniae isolates in Argentina [209]; OXA-204 (two substitutions at Gln98His 
Thr99Arg) was reported from K. pneumoniae isolates isolated  from patients having 
a connection with North Africa [210]; OXA-232 (single replacement at Arg214Ser) 
was first detected in France in a K. pneumoniae isolate recovered from a patient who 
had been transferred to Mauritius from India [211]; OXA-247 (two substitutions at 
Tyr211Ser and Asp212Asn) was identified in a K. pneumoniae isolate recovered in 
Argentina [212]; OXA-244 (single substitution at Arg214Gly) and OXA-245 (single 
substitution at Glu125Tyr) were found in K. pneumoniae isolates in Spain [213]; 
OXA-370 (single substitution at Gly220Glu) was reported from Brazil [214] and 
OXA-405 (four deletions at Thr213 to Glu216) was identified in France [206]. 
Some OXA-48-like variants such as OXA-48, OXA-232, OXA-181, OXA-





211]. Remarkably, OXA-163 and OXA-405 have marginal hydrolytic activity 
against carbapenems, but displayed capacity to hydrolyze aztreonam and 
ceftazidime, and they both show an increased ability to hydrolyze cefotaxime and 
cefepime over OXA-48, making these enzymes resemble ESBL enzymes more than 
carbapenemases [209, 211]. 
The dissemination of the OXA-48 enzyme is facilitated by the rapid spread of 
a conjugative broad host-range plasmid harboring the blaOXA-48 gene located on a 
composite transposon, namely Tn1999 [142, 198, 199, 201, 215, 216]. The blaOXA-48-
like genes are commonly observed on IncL/M plasmids, which do not harbor extra 
resistance genes, and are 60–70 Kilobase pair (Kb) in size [217]. The IncL/M 
plasmids are considered a major resistance plasmid family recognized in clinically 
significant Enterobacteriaceae [140]. The high transfer ability of the epidemic 
IncL/M plasmid is the reason suggested for the successful dissemination of blaOXA-48 
in Enterobacteriacea [121, 218]. 
On the other hand, the international spread of OXA-48-type carbapenemases 
is attributed as well to the success of OXA-48–type-producing clones, and, to a lesser 
extent, to certain regions (e.g. the spread of OXA-181 in the Indian subcontinent) 
[167, 199, 215]. blaOXA-48-like genes were also reported to spread in strains belonging 
to different K. pneumoniae STs (ST101, ST11, and ST14) endorsing the ability of 
high-risk clones to accumulate resistance determinants [219-221]. 
There is an inter-regional spread of OXA-48-producing K. pneumoniae 
rendering it endemic in a number of European countries: Spain, France, Belgium and 





described globally in Enterobacteriaceae. Dissemination of OXA-48-like producing 
CRE in the Middle East was reported from Lebanon, Saudi Arabia, the United Arab 
Emirates and Israel [155, 222, 223]. In Africa, it was reported from Egypt, Algeria, 
Libya and South Africa [224-227]. OXA-48-like producer Enterobacteriaceae were 
also encountered in several Asian countries: India, China, Taiwan, Thailand and 
Russia [228-232]. OXA-163 is especially prevalent in South America [233, 234].  
1.7 The role of Klebsiella pneumoniae clones in spreading carbapenem 
resistance 
As outlined earlier, the spread of antibacterial resistance has two main routes: 
dissemination of resistant bacterial clones and horizontal gene transfer. In the 
following section, the role of high-risk (HiR) clones of Klebsiella pneumoniae will 
be discussed, as they play a major role in the global dissemination of CRE [235].  
The significance of HiR bacterial clones in the setting of worldwide spread of 
antibiotic resistance was first documented by Woodford et al. [235]. A ‘high-risk 
clone’ was defined as group of isolates that share the same ST established by 
multilocus sequence typing (MLST), even if isolates have been collected from 
distinct geographic locations and time. HiR clone have a high ability to spread, 
colonize, and persist in a range of ecological niches [236]. The HiR clones have 
attained definite adaptive traits that increase their pathogenicity and existence, apart 
from the acquisition of antibiotic resistance determinants. Such clones have 
contributed to the global spread of antibiotic resistance, and they are also considered 
as a source of the propagation of genetic components of antimicrobial resistance such 






Furthermore, it was reported that some definite K. pneumoniae STs are 
considered to be outbreak-causing infectious agents more than others [235, 237]. The 
frequency of outbreaks caused by a bacterial clone signifies its epidemic potential. 
Therefore, these are the clones that should be recognized, examined and controlled. 
The definition of HiR clone has been laid out by Navon-Venezia et al.: clones that 
caused at least four known outbreaks and were reported from ≥10 countries [238]. 
Accordingly, nine HiR worldwide disseminating MDR and XDR K. pneumoniae 
clones were recognized : CC258 (ST258, ST11, ST512), CC15 (ST15, ST14),  
ST147,  ST37, ST101 and ST17, all of which were known to be carbapenem resistant 
K. pneumoniae from earlier studies [238]. All nine sequence types demonstrated 
international spread in three to five continents. The most significant of them causing 
68% of all outbreaks, was CC258 which consists of three STs: ST258, ST11 and 
ST512. The second most prevalent CC, responsible for about 20% of all outbreaks, 
was CC15, consisting of ST14 and ST15. Other STs were epidemic but to a lower 
degree [238].   
1.7.1 Dissemination of Klebsiella pneumoniae ST258 clone 
The emergence and worldwide dissemination of K. pneumoniae ST258, and 
reports showing that this clone has propagated as a result of recombination and 
replacement of the cps locus, raise the question of its evolutionary history. A study 
showed that ST11 (allelic profile 3-3-1-1-1-1-4), a single-locus variant of ST258 
(allelic profile 3-3-1-1-1-1-79), and an extremely predominant multidrug-resistant 
clone in South America and Asia [151, 239, 240], gave rise to the ST258 clone 





hypothesized that K. pneumoniae ST258 is a hybrid clone that was produced by a 
large recombination event between K. pneumoniae ST11 and K. pneumoniae ST442 
[116]. 
Numerous reports highlighted a number of superior features of CC258 that 
might be linked to its successful prevalence worldwide. Genomic comparison studies 
revealed the existence of 50 unique genes present in ST258 clone and absent in a 
non-ST258 sporadic clone (ST376), those genes were linked to cell motility, 
secretion, DNA modification and repair [237]. 
A different study described an integrative conjugative element, ICEKp258.1, 
carried by K. pneumoniae ST258 and ST11, encoding a type IV secretion system, 
that probably assists the propagation of mobile elements [242]. Another element, 
ICEKp258.2, present  in K. pneumoniae ST258 and in its descendant K. pneumoniae 
ST512, encodes a type III restriction-modification system and a type IV pilus gene 
cluster, which possibly improve adherence abilities and narrow the range of 
compatible plasmids and other mobile elements [116]. This may explain the low 
diversity of carbapenemases in K. pneumoniae ST258 and ST512 compared to K. 
pneumoniae ST11 [238]. Moreover, K. pneumoniae ST258 showed low 
susceptibility to chlorhexidine, a disinfectant used in hospitals, thus suggesting its 
selective advantage in the hospital environment compared to other sporadic KPC-
producing clones [243]. 
ST258, the most prevalent clone of this CC, is considered the main driving 
force of worldwide spread of KPC enzyme [30, 132, 244]. ST258 outbreaks were 





reported from Greece [245], Israel [246], Finland [247], Italy [248], Germany [249], 
Denmark [250] and the USA [132]. K. pneumoniae ST512, as well, was found to be 
exclusively linked to blaKPC [30, 251]. 
In Hungary the first isolate with a KPC enzyme was found to belong to K. 
pneumoniae ST258. It was reported to harbor blaKPC-2, blaSHV-12, blaTEM-1 and  
blaSHV-11 [252]. Worryingly, in Hungary the same KPC-2 producing clone was 
reported exhibiting colistin resistance, as well [252]. 
In 2009, the emergence of the first isolate with KPC carbapenemase 
producing isolates of K. pneumoniae ST258 clone in Norway and Sweden was 
documented [253, 254]. K. pneumoniae ST258 with KPC-2 in Poland was also 
documented [255], which resembled the KPC producer isolates found in Norway and 
Sweden [254]. These findings strongly support the prominent role of this group in 
the dissemination of blaKPC.  
Therefore, K. pneumoniae ST258 is considered as the dominant 
carbapenemase-expressing lineage in much of North America and Europe [256].  
1.7.2 Dissemination of Klebsiella pneumoniae ST11 clone 
K. pneumoniae ST11, a single-locus variant (tonB) of the international 
hyperepidemic ST258, is also a high risk clone [241]. K. pneumoniae ST11 lineage is 
predominant in China, South Korea, and Hungary [239, 257-259], and has also been 
widely documented in New Zealand, Poland, Spain, Singapore and Brazil [130, 260-





M-14 [252, 257, 260, 265], and later with various carbapenemases: KPC-2 [239, 254, 
266], VIM [267, 268],  OXA-48 [261, 269] and NDM [270, 271].  
Recently in Spain, the emergence of colistin resistant K. pneumoniae ST11 
expressing OXA-48 and CTX-M-15 was reported [261]. Another report described 
the prevalence of OXA-48-producing K. pneumoniae ST11 clone throughout Spanish 
hospitals. [272] A fatal outbreak of carbapenem resistant, hypervirulent K. 
pneumoniae ST11 was reported from a Chinese hospital [273], heralding the 
emergence of true ‘superbugs’, which are not only being multidrug resistant and 
hypervirulent, but also extremely transmissible, initiating severe and even fatal 
infections [273]. 
The success of K. pneumoniae ST11 clone is not fully understood. A possible 
explanation is that K. pneumoniae ST11 clone possesses seven cps locus types, 
compared to one or two loci found in other clones, thus it was proposed that the 
divergence in capsular content may obscure the recognition of this clone by the 
immune system [274]. 
K. pneumoniae ST11 associated with blaNDM-1 was identified in many 
countries: USA [184], Australia [275], Switzerland [276], Greece [277],  the Czech 
Republic [278], Spain [279], Thailand [280] and the UAE [281]. The Polish outbreak 
of NDM-producing K. pneumoniae ST11 was likely introduced from the Czech 
Republic, as the clone in Poland was similar to an isolate found in the Czech 
Republic in 2013 [282], thus supporting the local dissemination of this clone. ST11 





[279, 283]. Furthermore, the majority of NDM-producing K. pneumoniae isolates 
found in India belonged to either ST11 or ST147 [283].  
K. pneumoniae ST11 is one of the major clones spreading KPC-2 
carbapenemase in China [144, 284], and was reported to be associated with 
dissemination of the same carbapenemase in Singapore as well [264]. 
Moreover, from a multicenter survey of ten university hospitals in South 
Korea, K. pneumoniae ST11 isolates were the most prevalent having at least eight 
different ESBL genotypes, but none had KPC enzymes, implying that ST11 was 
widespread independently of KPC carbapenemase. Possibly, multiple acquisition 
events led to the presence of multiple variants of the clone circulating in South Korea 
[257]. 
1.7.3 Dissemination of Klebsiella pneumoniae CC15 (ST15 and ST14) 
K. pneumoniae ST15 has been recognized as a HiR K. pneumoniae clone 
disseminating ESBLs and carbapenemase enzymes worldwide. It has recently been 
reported to carry CTX-M-15 from various countries including Bulgaria [285], 
Netherlands [286], Japan [287] and Brazil [288]. This clone was also reported with 
all types of carbapenemase genes: blaNDM, blaOXA-48-like, blaVIM, blaIMP and blaKPC 
[238]. NDM-producing members of this clone were described from Croatia [289], 
Canada [290], China [291], and Thailand [280]. VIM producing K. pneumoniae 
ST15 was encountered in Spain [279] and Hungary [292]. Moreover, KPC-2 





K. pneumoniae ST14 differs from ST15 by the infB allele only. Previous 
reports presented ST14 as a high-risk clone, due to its high ability to disseminate 
worldwide (illustrated in Table 1) and to host multiple β-lactam resistance 
determinants including ESBLs (blaCTX-M-15, blaSHV, blaTEM), AmpC 
cephalosporinases (blaFOX, blaCMY) and carbapenemases (blaKPC, blaNDM-1, blaOXA-48-
like)[157, 233, 294, 295].   
On the other hand, K. pneumoniae ST14 clone has been mostly described as a 
frequent host of CTX-M enzymes and was reported as a host lineage of NDM-1 
enzyme [235, 271]. 
In addition, K. pneumoniae ST14 clone have been extensively reported with 
capsular serotype K2, which is one of the most reported K.pneumoniae serotype 
linked to invasive diseases [296-299]. Another study that was conducted to identify 
K. pneumoniae hypervirulent clones of capsular serotype K2 proved that the most 

















No. of ST14 isolates 
reported 
Reference 
blaNDM-1 2009 India 1 [174] 
blaNDM-1 2011 Oman 1 [301] 
blaNDM-1 2011 Kenya 7 [192] 
blaNDM-1 2012 India 10 [299] 
blaNDM-1 2012 UK 2 [299] 
blaNDM-1 2012 Sweden 1 [299] 
blaKPC-2 2012 USA 2 [147] 
blaNDM-1 2012 India 2 [283] 
blaOXA-181 2012 Finland 1 [302] 
blaOXA-181 2014 South Africa 2 [303] 
blaOXA-48 2015 Germany 6 [295] 
blaNDM or blaOXA-48 2015 Ireland 2 [304] 
blaNDM-1 2015 UAE 7 [156] 
blaNDM-1 2015 Singapore 1 [305] 
blaKPC-2 2015 UAE 2 [157] 
blaKPC-2 2015 Colombia 16 out of 193 (8.2%) [306] 
blaKPC-3 2015 USA 1 [307] 
blaKPC-3 2017 USA 1 [45] 
blaNDM−5 2017 China 1 [308] 
blaNDM-1+blaOXA-232 2017 India 3 [309] 
blaKPC-2 2017 UK 1 [294] 
blaNDM-1+ blaOXA-48 2018 Pakistan 3 [310] 










1.7.4 Dissemination of other high risk Klebsiella pneumoniae clones (ST147, 
ST37, ST101 and ST17) 
K. pneumoniae ST147, ST37, ST101 and ST17 clones were reported to carry 
KPC-, NDM-, VIM- and OXA-48-like carbapenemases worldwide [238], but before 
the emergence of these carbapenemases, most of them were already spreading CTX-
M-type ESBL enzymes [312] highlighting their outstanding ability to disseminate 
antibiotic resistance determinants. K. pneumoniae ST147 was also reported to co-
harbor more than one carbapenemase genes in various combinations [313, 314], and 
to develop into a pan-drug resistant bacterium [314, 315]. Furthermore, like K. 
pneumoniae ST11, carbapenemase producer strains of this clone has also been 
reported to carry genetic determinants of hypervirulence [316]. 
1.7.5 Carbapenemase producer Klebsiella pneumoniae clones encountered in the 
Arabian Peninsula 
NDM and OXA-48-like carbapenemases are considered the major 
carbapenemases found in Enterobacteriacea in countries of the Arabian Peninsula 
[156, 194, 317-319]. This is in sharp contrast to the dominance of the KPC-type 
enzymes experienced in many parts of the world [320]. In this region only sporadic 
cases of KPC-producing Enterobacteriaceae have been reported [157, 321, 322]. 
VIM carrying strains were mostly encountered sporadically too [156, 173, 322-325], 
however, between 2009 and 2011 there was a temporary elevation in VIM producing 
clonally unrelated Enterobacteriaceae in Kuwait [326], which was due to a plasmid 
outbreak [172]. Several K. pneumoniae sequence types have been described from the 
region: ST29 was the major clone responsible of an OXA-48-producing CRKP 





of ST199, ST152, ST37, ST48, ST340, ST15 and ST16 were detected. In that study a 
significant link was observed between carbapenemase genes and the clonal types of 
K. pneumoniae: ST152 was reported as a frequent carrier of the blaNDM-1 gene, while 
ST199 isolates were positive for blaOXA-48 [328].  
In a collection of CRE isolates of Saudi Arabia, UAE, Oman and Kuwait 
three major clones of blaNDM-1 producing K. pneumoniae were detected: ST152 from 
Saudi Arabia, ST14 from the UAE and ST147 from Oman, with blaNDM-1 detected on 
HI1b incompatibility type plasmids in both the ST14 and the ST147 isolates [156]. In 
this study, the blaNDM-1 was the most common carbapenemase, followed by non-
clonal CRE, mostly K. pneumoniae harboring blaOXA-48 [156].  
In the UAE, single cases of K. pneumoniae ST29, ST1425, and ST340 
producing OXA-48 were detected in bloodstream infections in Abu Dhabi [222]. 
Furthermore, the occurrence of a pan-drug resistant K. pneumoniae ST147 producing 
OXA-181, and in certain isolates also NDM-5, was reported from multiple hospitals 
and geographical regions of the UAE [314].  
In Oman, NDM-1 producer K. pneumoniae was associated with five different 
STs: ST147, ST15, ST11, ST101, ST372, while OXA-48 producing K. pneumoniae 
belonged to ST753, ST754 [319].  
K. pneumoniae strains co-producing two carbapenemases were reported from 
Oman [319], Saudi Arabia [317] and UAE [314, 329]. In Oman an OXA-181 and 
NDM-1 co-producing ST11, in Saudi Arabia OXA-48 and NDM-1 co-producing 





and ST14 producing OXA-232 and NDM-1 was noted [314, 329]. Furthermore, 
ST307 and ST1318 co-producing NDM-1 and OXA-162 or NDM-1 and OXA-48, 
respectively, were encountered [329].  
1.8 Spread of antibiotic resistance by horizontal gene transfer  
Mobile antibiotic resistance genes are confined in platforms that include 
plasmids, integrative and conjugative elements (ICEs) [330], integron cassettes and a 
range of transposons and related elements. All these are recognized as mobile genetic 
elements (MGEs). MGEs can transfer by a variety of molecular mechanisms, 
including transduction, transformation and conjugation (Figure 1).  
 
Figure 1: Acquisition of antibiotic resistance genes [331] 
Transduction is mediated by a bacteriophage (bacterial virus), which 
facilitates the transfer of host DNA from one bacterium to another. It does not 
require cell to cell contact [332]. Transduction have been reported to transfer 
antibiotic resistance genes both intra- and interspecies. Transformation is the process 





Bacteria that have the ability to endure transformation is termed as “competent” 
[333].  Conjugation is a procedure where a conjugative element such as a plasmid or 
a transposon is transferred between bacteria via a contact dependent 
semiconservative replication process. Plasmid mediated conjugative transfer is by far 
the most common mechanism of horizontal gene transfer in Gram negative bacteria 
[334]. 
1.8.1 Integrative and conjugative elements 
The foremost types of mobile elements currently involved in the capture and 
mobilization of antibiotic resistance genes found in Gram-negative bacteria are 
certain insertion sequences (IS) [335], gene cassettes/integrons [336] and transposons 
of the Tn3 [337] and Tn5053 families [338] (Figure 2). These elements have some 
features in common, but capture and/or move genes by different mechanisms [339]. 
 
Figure 2: Characteristics of mobile elements in Gram-negative bacteria involved in 





Insertion sequences (IS) are small transposable segments of DNA (<2.5Kb) 
with a simple genetic organization. Most IS elements display short terminal inverted-
repeat sequences (IR) and code for a transposase, an enzyme that is essential for 
transposition and has recombinase activity [340]. These mobile elements play a 
major role in assembling of “accessory” functions in bacteria (as genes essential for 
catabolic pathways) and in spread of resistance genes. By inserting within a coding 
sequence they may render the gene inactive, or by inserting upstream of a gene they 
may adjust its expression. ISs may also assist the integration of plasmids into the 
bacterial chromosome. Some ISs are capable of mobilizing nearby DNA by a process 
similar to one-ended-transposition (such as ISEcp1), whereas others form a 
composite transposon, thus being able to carry the sequence situated between the two 
ISs [341].  
Transposons such as the large group of type II transposons of the Tn3 family 
and Tn7 are complex structures and contain integrons carrying multiple antibiotic 
resistance genes. This association of transferable elements with integrons stimulates 
rapid spread among clinical strains, and creates more occasions for inclusion of extra 
resistance determinants. A transposon is a composite form of IS, surrounded by 
inverted ISs on both extremes and consequently have the ability to carry more than 
one genetic determinant. Transposons may lead to complex DNA rearrangements 
and may accumulate several resistance genes to form an MDR phenotype [342].  
Integron is a genetic structure which has the ability to capture and 
simultaneously express several antibiotic resistance genes. It is formed of an 





element, which enables the gene to integrate to an integron. Integrons may carry 
multiple resistance determinants concurrently, and they may be located on a 
transposon, ensuring their mobility [343, 344].  
1.8.2 Plasmids 
A plasmid is an independently replicating extra-chromosomal, circular, 
double-stranded DNA molecule, which does not carry genes essential for the growth 
of host cells under non-stressed conditions [345]. However, once gained, they can 
become essential for bacterial survival. Plasmids have systems, which guarantee their 
self-directed replication (independently from the replication of the bacterial 
chromosome) while controlling their copy number and assuring stable inheritance 
during cell multiplication [346, 347]. The part of the plasmid that maintains copy 
number of parent plasmid with controlling the initiation of replication is termed as 
the basic replicon [348].  
Several plasmids have accessory genes that are useful not only to themselves, 
but also to their host, e.g. genes controlling drug resistance, degradation of organic 
compounds, colonization of new habitats and virulence factors (including production 
of toxins). These types of genes are mostly located within transposons, leading to a 
great variation and flexibility in the composition of plasmids [217, 331]. 
A plasmid’s success depends upon a balance of multiple factors, including 
horizontal transfer through the conjugation process among bacteria of different 
genera and kingdoms, segregation error rate (vertical transfer), post-segregation 
killing, fitness cost, and compensatory mutations which can occur to reduce fitness 





population despite other selective pressure. Conjugation alone is considered enough 
to stably maintain a high fitness cost plasmid, even in the absence of any selective 
pressure [349, 352]. 
Promiscuous, broad-host-range plasmids usually have the restriction/anti-
restriction mechanisms and partitioning systems, guaranteeing stable inheritance 
throughout cell division. A lot of plasmids encode also addiction systems based 
generally on toxin–antitoxin factors, which have the ability to destroy daughter cells 
that fail to inherit the plasmid during cell division [346]. These systems support 
plasmid maintenance, but do not provide any benefit to the bacterial host.  
Plasmids exist in a cell in a definite number of copies, maintained and 
controlled by their origin of replication [353]. Introducing either a low or a high copy 
number plasmid into cells lacking any plasmid has revealed that the copy number is 
commonly fixed by controlling the initiating of replication [354, 355]. Several 
mechanisms to maintain the copy number of plasmids isolated from E. coli have 
been described, but all approaches use negative regulation tactics. In one set of 
plasmid types, the quantity of the produced initiator protein is controlled by a 
specific inhibitor [353]. In another mechanism, multiple binding sites compete with 
the origin for binding to a small pool of initiator protein. In a third strategy, an RNA 
molecule that is essential for initiation is prohibited from binding to the origin by a 
second RNA and a protein. These approaches control the initiation frequency of 
DNA replication. 
Upon cell division, both daughter cells inherit plasmid molecules. In case of 





at least a few. As a result, it is not essential for plasmids with high copy number to 
have a strict control to segregate or partition plasmid molecules into daughter cells 
[353]. However, one of the issues faced by the high copy number plasmids during 
partitioning is the multi-number formation among plasmid copies. This will hinder 
the plasmid segregation, thus plasmids encoded genes are needed to maintain the 
stability of the plasmid. An example is the cer gene (present in ColE1 plasmids of 
high copy number), which encodes a product that converts plasmid multimers into 
plasmid monomers. This makes sure the independent partition of all copies of the 
plasmid. Although cer ensure the stability of ColE1 plasmids, it is not vital for 
maintenance of ColE1 in a population [356]. 
On the other hand, in case of low copy number plasmids (less than 10 copies 
of plasmids per chromosome) partition into daughter cells is much more critical. As 
there are limited number of plasmid copies, if one daughter cell receives two 
molecules, the other daughter may not inherit any plasmid molecule. Thus, those 
types of plasmids have mechanisms to ensure their right partitioning (Figure 3). An 
example of partitioning system is the parAB-parS system, where ParA and ParB 
proteins (produced by the plasmid) bind to the parS (centromere) sequence forming 
the parS-parA-parB complex that have the function of aligning all the of the plasmid 
molecules in the middle of the cell until division starts, afterward the plasmid 
molecules are partitioned into daughter cells by the combined action of ParA/ParB 
pushing the plasmids apart. As a result the low copy number plasmid is properly 
segregated into the daughter cells. This is a process similar to the partitioning of 






  Figure 3: Partitioning of low copy number plasmids [358] 
Transfer of plasmids from a donor cell to a recipient is called conjugation. 
Conjugation process involves two sets of plasmid genes, the mobility (MOB) genes 
and the mating pair formation (MPF) genes, together with an origin of transfer (oriT) 
[359]. The MOB genes code for both a relaxase and a DNA processing proteins 
(which are essential for the relaxosome and formation of coupling protein that links 
the relaxosome to the mating channel). MPF genes encode for the membrane–
associated mating pair formation complex, a system of type 4 secretion system 
(T4SS) that offers the mating channel [359]. The early step in the conjugation 
process is the formation of mating pair, where the donor and recipient get cell to cell 
direct contact. The next step includes relaxase-mediated nicking of the plasmid at 
oriT thus creation of the relaxosome (coupling of single-stranded DNA with a 
protein complex). The relaxosome docks to the coupling protein,  which assist to 
initiate the transport through the T4SS into the recipient cell, then establishment and 





1.8.2.1 Characteristics of the large resistance plasmids 
Plasmids conferring multi-drug resistance are usually large (>50 Kb), self-
conjugative and encode special mechanisms regulating their copy number and 
controlling the rate of replication [347]. The minimal portion of the plasmid that 
replicates with the characteristic copy number of the parent plasmid is called basic 
replicon [361]. Replicons comprise of the origin of replication (ori) and encode 
definite replication initiator proteins (Rep) that bind to the ori and to their regulating 
factors [361, 362]. The strict control of replication suggests that two plasmids that 
share the same replicon cannot propagate stably in the same cell line. This 
phenomenon is known as plasmid incompatibility [358]. 
1.8.2.2 Plasmid typing  
Identification and classification of plasmids should be established on genetic 
traits that are universally present and constant. These criteria  are best met by 
qualities concerned with plasmid maintenance, especially replication controls [363] . 
A plasmid classification scheme was suggested by Datta and Hedges in 1971, 
it was established on the stability of plasmids during conjugation, a phenomenon 
called plasmid incompatibility [364, 365]. Incompatibility is a representation of the 
relatedness of plasmids that have common replication controls [364, 366]. 
Incompatibility was well defined as the incapability of two related plasmids to 
propagate stably in the same cell line; thus, compatible plasmids only can be stably 
maintained in transconjugants (TC). In other words, it is the determination of the 
transfer frequency of plasmid in different groups together with their stable co-





The initial incompatibility (Inc) groups were defined as follows: W (named 
after a reference strain received from Tsutomu Watanabe) [367]; IncI plasmids 
(producing type I pili while being susceptible to phage Ifl); IncN (N3-related 
plasmids susceptible to phage Ike); IncF (plasmids producing type F pili susceptible 
to phage Ff); and IncP  (RP4-related plasmids susceptible to the PRR1 phage) [364, 
365].  Later, updates on this scheme was done and 23 plasmid incompatibility groups 
were identified B, C,D, E, FI, FII, FIII, FIV, H, Ia, I2, Ic, Id, If, J, K,M, N, P, T, V,W 
and X . Further annotation and modification were made, e.g. plasmids that where 
incompatible with IncA and IncC were referred as IncA/C, former IncL were 
renamed as IncM, and those previously named IncL became IncL/M[368] . 
Among Enterobacteriaceae 28 Inc groups have been recognized so far, in 
Pseudomonas 14, and around 18 in Staphylococcus [369].  Currently, the plasmid 
typing scheme frequently used is Inc/rep typing. This typing is generally consistent 
with the conjugation dependent scheme. 
 The first replicon typing scheme was established in 1988, based on Southern 
hybridization:  a genetic plasmid typing scheme using cloned replication regions 
(replicons) as probes was identified by Couturier and colleagues [362]. This method 
efficiently offered classification for both conjugative and non-conjugative plasmids. 
However, it could not be easily applied to a large number of isolates as it was limited 
by the time consuming work. Furthermore, with the low specificity of the 
hybridization method, it undervalued plasmid variety due to the cross-hybridization 
reaction among highly related replicons (repI, repB/O, repFII, repFIC). Thus it was 





Since 2005, a PCR-based replicon typing (PBRT) scheme has been presented 
by Carattoli et al. [371] using a set of primers targeting different regions (rep gene, 
iterons, RNAI) of the major plasmid families found in Enterobacteriaceae (HI2, HI1, 
I1-γ, FIA, X, L/M, A/C, N, FIB, FIC, W, Y, P, T, B/O K) and also having additional 
PCR assays (FrepB and FIIAs PCRs), detecting the FII, FIII, FIV, and FIV variants 
and the FII replicon of the Salmonella virulence plasmids, respectively [371]. Targets 
for further identification of other plasmid groups have been added to the typing 
system by Villa et al. [372] and Garcia- Fernandez et al. [373].  
With the advent of next generation sequencing and its use in bacterial 
genome sequencing, the data generated by this method became available for plasmid 
identification and typing. The web-based tool, PlasmidFinder can be used for in 
silico detection and typing of plasmids [374]. 
Further to that, in order to increase the sensitivity of detecting low-copy 
plasmid replicons, real-time PCR was proposed by Boot et al. [375]. Moreover, a 
scheme was proposed by Bousquet et al.[376] that can be used together with PBRT; 
whereas diverse partition systems located on MDR plasmids were described, which 
led to the design of a multiplex PCR method termed as plasmid partition gene typing 
(PAR-T). This technique can be used for a further plasmids classification in K. 
pneumoniae, Salmonella enterica spp. and E. coli [376]. 
An additional approach, known as plasmid multilocus sequence typing 
(pMLST) has been developed for IncN, IncA/C and IncI plasmids; it is used to 
increase the discriminatory power in the differentiation and characterization of 





evolutionary and epidemiological relatedness [377-379]. 
Multi-replicon plasmids impose a challenge for plasmid replicon typing. One 
of the best known multi-replicon plasmid is the IncF which can have an FII, FIA 
and/or FIB replicon. Moreover, other plasmids can co-integrate, generating another 
form of multi-replicon plasmid [380-382]. These as well, are challenging for typing 
and understanding of plasmid epidemiology.  
Francia et al. and Garcillan-Barcia et al. have offered the use of conjugative 
relaxases as a plasmid-typing tool. Relaxase-based typing can be applied to any 
plasmid (immobilizable or conjugative) [383, 384]. Another major benefit of this 
system is that while a plasmid can have multiple replicons, there is always only one 
relaxase per plasmid. Since relaxases are said to be stable markers of plasmid 
evolution, they represent better evolutionary relatedness. 
Nevertheless, all these PCR based typing schemes have some limitations. 
Therefore, the most accurate method to characterize a plasmid is based on the 
determination of the full-length DNA sequence [140]. 
1.8.2.3 Resistance plasmids of Enterobacteriacea 
Plasmids of the family Enterobacteriaceae have been categorized into 
replicon (Inc) types by PCR-based replicon typing (PBRT) [385, 386]. PBRT, in 
combination with other characteristics of the bacterial host, such as serotype, 
sequence type (ST) by MLST and resistance gene profiles, is used to demonstrate the 
spread of antimicrobial resistance determinants between genetically unrelated 





In Enterobacteriaceae, IncHI, IncF, IncL/M, IncA/C, IncI1, and IncN 
plasmids are considered to be the predominant plasmid families responsible for 
worldwide dissemination of carbapenemase, AmpC cephalosporinase, ESBL, and 
PMQR genes [140, 217]. 
1.8.2.3.1 IncF plasmids 
IncF plasmid’s host range is limited to the Enterobacteriacea family. They 
have been reported in almost all species in this family. IncF-related plasmids are low 
copy number, conjugative with size ranging from 45-200Kb [371]. IncF plasmids are 
known to be typical multi-replicon plasmids, carrying the FII replicon together with 
the FIA and FIB replicons. Moreover, co-integration of IncI1 and IncN replicon type 
plasmids into IncFII has been reported [382, 388]. 
Based on PCR and sequencing, IncFII plasmid family are subcategorized to 
the FIIk (Klebsiella), FII (E. coli), FIIs (Salmonella) and FIIy (Yersinia) specific 
groups [372]. 
Resistance genes that have been frequently described on IncF plasmids are 
genes encoding ESBLs, carbapenemases, AMEs and PMQR genes [319, 389]. The 
international dissemination of blaCTX-M-15 in E. coli and K. pneumoniae isolates is 
extensively related to IncF plasmids [390-392]. 
FIIk is regularly described with replicons of the FIB-type [374]. Two kinds of 
FIB replicons have been stated more commonly in K. pneumoniae plasmids, termed 
FIBpKPQIL and FIBpKPN. These FIB replicons differentiate plasmids pKPQIL and 





These plasmids are rarely reported from other enterobacterial species, which may be 
due to the narrow host range features of IncFIIk plasmids limiting their spread. The 
occurrence of these plasmids in K. pneumoniae beside their role in biofilm formation 
and iron scavenging may be the reason for persistence and survival of K. pneumoniae 
within hospitals and patients [395]. 
1.8.2.3.2 IncA/C plasmids 
IncA/C plasmids are low copy number, conjugative and self- transferable 
episomes with a size range of 40–230 Kb. According to the PBRT scheme the target 
gene is repA. IncA/C plasmids have a wide host range [396]. Two variants have been 
described within this group: A/C1 and A/C2; both IncA/C1 and IncA/C2 show 26 
single nucleotide polymorphisms in the repA gene [397]. IncA/C plasmids have been 
found globally and are associated with MDR; they have been documented with 
ESBLs, AmpC beta lactamases, carbapenemases such as KPC-2, NDM-1, NDM-6, 
NDM-7 and VIM-4 [173, 389, 398, 399], and have been associated with other 
antibiotic resistance genes, i.e. tetracyclines (tet(A)), aminoglycosides (aadA, aphA1, 
aacC, strA, strB), chloramphenicol (floR, catA1) and trimethorprim (drfA)  [400, 
401]. 
1.8.2.3.3 InHI plasmids 
IncHI plasmids have a wide host range, including Enterobacteriacea and 
other Gram negative bacteria [402]; they are a group of low copy number plasmids 
with a size ranging from 75 to 400Kb. The IncHI plasmid group has been 
distinguished into two groups as some members showed incompatibility with IncF 





plasmids but IncHI2 group is compatible with IncF plasmids [403].  
IncHI plasmids have been reported to carry carbapenemase genes [319, 404, 
405]; They are multidrug resistance plasmids, beyond genes encoding beta-
lactamases including carbapenemases, they usually carry aminoglycoside, 
sulphonamide, streptomycin and tetracycline resistance genes [319, 404]. 
1.8.2.3.4 IncL/M plasmids  
IncL/M are a broad host- range plasmids, their size range is 50-80Kb with a 
low copy number [406]; In the PBRT scheme repA, repB and repC are the target 
sites used.  
A 60 Kb IncL/M plasmid is extensively reported worldwide associating with 
blaOXA-48.  K. pneumoniae bearing these IncL/M plasmids with blaOXA-48 are 
considered a major cause of infection in hospitals [130, 319, 407]. 
One of the main causes of the successful spread of this plasmid is owed to the 
Tn1999, that harbor the blaOXA-48, Tn1999 inserts itself in the tir gene that encodes  a 
transfer inhibition protein [218].  
1.8.2.3.5 IncX plasmids 
IncX plasmids were identified in Klebsiella and Salmonella isolates in the 
pre-antibiotic era [408]. IncX plasmids are narrow host range plasmids, reported 
extensively in Enterobacteriaceae, with a size range from 30 to ~50 Kb [368]. They 
have six subtypes: IncX1 to IncX6 [409, 410]. Molecular examination of IncX 
plasmids revealed genes, which are necessary for replication (pir), pilus synthesis 





conjugation [411]. Moreover, these plasmids deliver accessory functions to their host 
bacteria, e.g. resistance to antibiotics and biofilm formation [412]. 
Members of this group have been found to carry a wide variety of resistance 
genes. For example, carbapenemases genes (mostly blaKPC and blaNDM) have been 
described on IncX plasmids from different parts of the world [399, 410, 413]. IncX 
plasmids have been involved in the acquisition and spread of transferable AMR 
determinants, such as ESBLs (blaTEM-52, blaCTX-M-15 and blaSHV-12), plasmid-mediated 
quinolone resistance genes (qnrS1, oqxAB) and colistin resistance genes (mcr-1). 
Furthermore, tetracycline and trimethoprim resistance determinants have been 
reported on IncX plasmids [230, 409, 410]. A special subgroup of the IncX plasmid, 
IncX3, has been described all over the world to carry various carbapenemase genes 
(blaKPC, blaNDM and blaOXA-181) in clinical isolates of Enterobacteriaceae, e.g. E. coli, 
K. pneumonia, Citrobacter freundii, Enterobacter cloacae and Serratia marcescens 






















blaNDM-1  2012 China 
K. pneumoniae, E. coli  
Citrobacter freundii, 
Enterobacter aerogenes,  
E. cloacae 
54 [414] 
blaKPC-2 2013 China K. pneumoniae 42 [415] 








blaKPC-2 2014 Brazil K. pneumoniae 45 [256] 
blaNDM-5 2014 China E. coli 47 [418] 
blaNDM-5 2015 India K. pneumoniae 46 [419] 
blaNDM-1 or 
blaOXA-181 
2015 China E. coli  51 [420] 
blaNDM-7 2013 Germany E. coli 60 [421] 
blaKPC-2 2015 UAE K. pneumoniae 45 [157] 
blaNDM-4 2015 Australia K. pneumoniae 46 [422] 
blaOXA-181 2015 China E. coli 51 [230] 
blaNDM-7 2015 Canada 
Serratia marcescens, E. 
coli, K. pneumoniae 
46 [423] 
blaKPC-3 2016 Italy K. pneumoniae 63 [424] 
blaOXA-181 2016 West Africa E. coli 54 [425] 




E. coli 34-36 [318] 
blaNDM-4 2017 Myanmar E. coli 46 [427] 
blaNDM-7 2017 Myanmar E. coli unknown [427] 
blaNDM-4 2017 India E. coli 45 [428] 
blaKPC-3 2017 Italy 
Serratia marcescens,  
E. coli, 
Citrobacter freundii 




















1.9 Research hypothesis, aims and objectives  
As shown in the previous sections antibiotic resistance, and specifically 
carbapenem resistance spreads both by dissemination of bacterial clones, as well as 
horizontal gene transfer. We hypothesized that both mechanisms contributed to the 
emergence of CRE in the UAE. Therefore, the aim of our study was to investigate 
the molecular epidemiology of carbapenem resistant Enterobacteriaceae in the UAE 
and its neighboring countries, with the following specific objectives:  
− To study how the IncX3 plasmid-borne carbapenemases emerged in the UAE, 
and to what extent they contributed to the spread of CRE in the country. 
− To assess the molecular epidemiology and antibiotic resistance of CRE 
collected systematically during a year-long period in five major hospitals of 
Dubai. 
− To compare by whole-genome sequencing the core genome and the variety of 
plasmids carrying carbapenemase genes in carbapenem-resistant Klebsiella 
pneumoniae ST14, i.e. a CRE clone increasingly encountered in countries of 






Chapter 2: Materials and Methods 
 
2.1 Bacterial isolates 
To study the IncX3 plasmids carrying carbapenemases in the United Arab 
Emirates (UAE), 334 non-repeat carbapenem resistant Enterobacteriaceae (CRE) 
strains isolated between April 2009 and December 2014 in 12 hospitals of the UAE 
and submitted to the Department of Medical Microbiology and Immunology, UAE 
University (UAEU) for identification of the carbapenemases produced, were 
included. This collection included 90 isolates described earlier in [156, 157, 417, 
431], and further 244 CRE isolated between May 2013 and December 2014 from six 
governmental hospitals of Abu Dhabi Emirate. 
In order to assess to what extent Klebsiella pneumoniae clones contribute to 
the spread of CRE in Dubai, Enterobacteriaceae exhibiting decreased susceptibility 
to either ertapenem, imipenem or meropenem according to the criteria set by the 
Clinical and Laboratory Standards Institute (CLSI) [432] at the time of their isolation 
were collected, between June 2015 and June 2016, from hospitals having the 
broadest medical and surgical profile in Dubai. From the governmental health sector, 
the 625-bed Dubai Hospital and the 786-bed Rashid Hospital covering 70% of the 
city’s governmental hospital capacity participated in the study. From the private 
health sector, the 254-bed American Hospital, the 280-bed Mediclinic City Hospital, 
and the 127-bed Welcare Hospital, altogether covering 35% of Dubai’s private 
hospital capacity, were involved in the study. For CRE collection no further selection 
criteria were applied when submitting strains for the study to the Department of 





To investigate the genetic relatedness and variations in carbapenem-resistant 
Klebsiella pneumoniae ST14 (CRKP-ST14), i.e. a sequence type increasingly 
encountered in countries of the Arabian Peninsula, we tested 761 independent CRKP 
isolated between June 2011-June 2016 in Bahrain (n=20), Kuwait (n=66), Saudi 
Arabia (n=151), Oman (n=41) and the United Arab Emirates (n=483). 
Until the investigations, all bacterial strains were stored at -80 °C in Tryptic 
Soy Broth (MAST, Merseyside, UK) containing 10% glycerol at the Department of 
Medical Microbiology and Immunology, UAEU.   
2.2 Antibiotic susceptibility testing 
For testing the antibiotic susceptibility, two approaches were used: broth 
microdilution and agar dilution. All tests were carried out and evaluated by the CLSI 
standards [432], except for tigecycline, colistin and fosfomycin for which no 
breakpoint values are available in this system. Thus, we used the EUCAST clinical 
breakpoints for interpretation of these latter antibiotics (www.eucast.org/clinical-
breakpoints) (EUCAST 2018).  
For the broth microdilution assay, antibiotics were serially diluted in 100 μl 
volume of Muller Hinton Broth (Oxoid, UK) in 96 well untreated microtiter plates 
(Sarstedt, Nümbrecht, Germany). Bacteria were inoculated using a Multipoint 
inoculator (MAST, UK) to give a final concentration of 105 CFU/ml. After 18 hours 
of incubation at 37 °C, the growth was visually assessed and the Minimum Inhibitory 
Concentration (MIC) of the drug was determined as the lowest concentration 
preventing visible growth of the organism tested. All tests were run in duplicates. 





meropenem (MEM), ertapenem (ERT), ceftazidime (CAZ), cefotaxime (CTX), 
aztreonam (AZT), ciprofloxacin (CIP), amikacin (AK), gentamicin (GN), 
trimethoprim-sulphamethoxazole (SXT), tetracycline (TET), chloramphenicol 
(CHL), and colistin (COL). For fosfomycin (FOS) and tigecycline (TGC), the agar 
dilution method was used to determine the MIC. Different concentrations of 
antibiotics were prepared in 1 ml and added to 24 ml molten Mueller Hinton Agar 
(MAST, UK). Plates with fosfomycin were supplemented with glucose-6-phosphate 
(Sigma, USA) at a concentration of 25 mg/L. One μl of 107 CFU/ml bacterial 
suspension was delivered by the multipoint inoculator to the surface of dry plates, 
i.e., approximately 104 CFU/dot was inoculated.  
For all sensitivity assays, Escherichia coli ATCC25922 was used as control. 
For testing colistin susceptibility ABC149, an mcr-1 producing E. coli ST131 was 
included as control with colistin MIC of 4 mg/L [433]. 
To group strains according to their level of resistance, the following 
categories were used: multi-drug resistant (MDR) if they were non-susceptible to ≥1 
agent in >3 antimicrobial classes tested, extensively drug resistant (XDR) if they 
remained susceptible to agents in ≤2 classes, and pan-drug resistant (PDR) if non-
susceptible to all antimicrobial agents tested.  
2.3 Determination of carbapenemase production 
Carbapenemase production was assessed using two phenotypic approaches, 






2.3.1 Modified Hodge Test (MHT) 
Mueller-Hinton agar plates (Oxoid) were inoculated with a 0.5 McFarland 
suspension of E. coli ATCC 25922. Meropenem disc was placed in the center of the 
plate. Whereas the test strain, a carbapenemase non-producing negative control strain 
(E. coli J53RAZ), and a KPC producing strain GR-KPC-2 (positive control) were 
streaked starting from the disc towards the plate edges. After 16-24 hours incubation 
at 37 °C, the plate was inspected for a cloverleaf-type indentation at the intersection 
of the test organism and E. coli ATCC 25922. 
2.3.2 CarbaNP test  
Carba NP test was performed as described by Nordmann et al. [434]. A 10 μl 
loopful mass of an overnight culture of the test strain on Tryptic Soy Agar (TSA) 
was mixed in 100μl of B-PERII, Bacterial Protein Extraction Reagent (Thermo 
Scientific Pierce, Rockford, IL, USA), vortexed for 1 minute and incubated at room 
temperature for 30 minutes followed by centrifugation of this bacterial protein 
extraction at 10,000×g for 5 minutes at room temperature. In a 96 well plate, 30 μl of 
the supernatant was mixed with 100 μl of phenol red solution (containing 0.05% 
phenol red and 0.1 mmol/L ZnSO4 adjusted to pH 7.8) supplemented with 3 mg/ml 
imipenem. As a negative control, the reaction was done in phenol red solution 
without the imipenem antibiotic.  Plates were incubated at room temperature for a 
maximum of 2 hours. For carbapenemase producers, the color of the wells turned 






2.4  Crude extraction of bacterial genomic DNA  
Three to five colonies, grown overnight on TSA with or without 0.5 mg/L 
ertapenem (according to the strain’s susceptibility), were picked by sterile toothpick, 
and suspended in 200 μl of DNase free distilled water. The suspensions were kept in 
thermoblock (Eppendorf, Germany) at 99°C for 10 minutes, then centrifuged for 10 
minutes at 14800 rpm. The supernatant collected in new sterile Eppendorf tubes was 
used as the DNA template in PCR reactions directly, or stored at 4°C.  
2.5 Polymerase Chain Reaction (PCR)  
PCR reactions for NDM, KPC, OXA, VIM and IMP were performed using 
primers and cycling conditions listed in Table 3. Negative controls used were the E. 
coli J53RAZ genomic DNA and ultra-pure distilled water. All PCR reactions were 
performed using the Applied Biosystems 2700 thermocycler and 2720 thermocyclers 
(Applied Biosystems, USA) using MicroAmp tubes (Applied Biosystems, USA).  
Finally, amplicons were analyzed on 1% agarose gel (Promega, US) using 
ethidium bromide dye (Sigma). Gels were then visualized and photographed using 
Biometra gel documentation system (Biometra, Gottingen, Germany) at 302 nm. 
To determine the alleles of blaOXA-48-like and blaNDM genes the primers and 
conditions listed in Table 4 were used to generate amplicons. 
DNA samples of isolates exhibiting resistance to colistin were tested for the 
presence of mobile colistin resistance genes (mcr-1, mcr-2, mcr-3 and mcr-4) 









Table 3: Primers and PCR reaction conditions for the detection of common carbapenemase genes 















10’ at 94°C 
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40X (30”at 94°C, 40” 




40X (30”at 94°C, 40” 




40X (30”at 94°C, 40” 
at 52°C, 50” at 72°C) IMP-R GGTTTAAYAAAACAACCACC 
blaNDM 
NDM1-Fo TGCCGAGCGACTTGGCCTTG 
379bp 5’ at 94°C 
30X (30”at 94°C, 30” 
at 60°C, 1’ at 72°C) 





























OXA-48 A TTG GTG GCA TCG ATT ATC GG 
744 
5’ at 94°C 
40X (30” at 94°C, 




OXA-48 B GAG CAC TTC TTT TGT GAT GGC 
blaNDM 
ASndm-1 GTC GCA AAG CCC AGC TTC GCA 
945 
40X (30” at 94°C, 
30” at 58°C and 1’ 
at 72°C) 
[437] 
























309 5’ at 94°C 
35X (30” at 
94°C, 30” at 
55°C and 1’ 
at 72°C) 




566 5’ at 95°C 
35X (30” at 
95°C, 30” at 
65°C and 1’ 
at 72°C) 




542 5’ at 95°C 
35X (30” at 
95°C, 30” at 
51°C and 1’ 
at 72°C) 




487 5’ at 95°C 
35X (30” at 
95°C, 30” at 
51°C and 1’ 
at 72°C) 








2.6 Molecular fingerprinting 
Pulsed Field Gel Electrophoresis (PFGE), Multi-Locus Sequence Typing, 
plasmid profile analysis, and core genome MLST (cgMLST) derived from bacterial 
whole genome sequences were used to establish the molecular types of the isolates. 
2.6.1 Macrorestriction of the genome followed by Pulsed Field Gel 
Electrophoresis (PFGE)  
The procedure of  Gautom et al. was followed [442]. Bacterial strains grown 
on TSA plates overnight at 37oC were suspended in 2ml of cell suspension buffer 
(100mM Tris: 100mM EDTA, pH8.0) and cell density was adjusted up to 2-3 
McFarland unit to ensure an optimum amount of bacterial cells present in the agarose 
plug. Suspensions were kept on ice. Concurrently, plug agarose (Sigma, USA) 
containing 1% SDS was prepared in TE buffer (10mM Tris: 1mM EDTA, pH8.0).  
In 1.5 ml Eppendorf tubes, 500 μl of bacterial suspensions were aliquoted and 
mixed with 25 μl of proteinase K (20 mg/ml) (Invitrogen) to inactivate the nucleases. 
The suspension was mixed with 525μl of 1% plug agarose and dispensed into 1 ml 
syringes and were left at room temperature for 15-30 minutes to allow the 
solidification of the agarose.  
One mm thick slices of agarose plugs were directly cut into aliquots of 5 ml 
cell lysis buffer (50mM Tris: 50mM EDTA pH8.0, 1% Sarkosyl) supplemented with 
25 μl proteinase K (20 mg/mL), then incubated at 50°C in a shaking water bath (200 
rpm) for 2 hours. Subsequently, the plugs were washed twice with 10 ml of 
preheated sterile MilliQ water for 20 minutes in a 50°C shaking water bath. 
Afterward, they were washed four times for 20 minutes with 10 ml of preheated TE 





Genomic DNA within the plugs was digested overnight at 37°C in a 100 μl 
restriction mixture made of 10 μl of cut smart buffer (New England Biolabs, UK), 30 
U (1.5 μl) of XbaI enzyme (New England Biolabs,UK) and 88.5 μl of sterile distilled 
water.  
Following digestion, the restriction mixture was removed and the plugs were 
incubated in 250 μl of 0.5X TBE buffer for 30 minutes at room temperature. 
Subsequently, plugs were inserted into wells of 1.4% of agarose gel (Pulse Field 
Running Agarose A2929, Sigma, USA) prepared with 0.5X TBE buffer.  
The two wells at the two sides of each gel and the middle well contained XbaI 
digested genome of Salmonella Braenderup H9812 as PFGE marker for 
standardization. Gels were run in CHEF Mapper (Biorad, USA) electrophoresis 
chamber containing 0.5X TBE buffer pre-chilled to 14°C. The running program 
consisted of 24 hours run at 6 V/cm with 120° angle and an initial switch time of 2.2 
seconds and a final switch time of 54.2 seconds with linear ramp.   
After electrophoresis, the gels were stained with ethidium bromide for 20 
minutes, followed by de-staining in 400 ml of sterile MilliQ water for another 20 
minutes. Using Biometra gel documentation system the genomic patterns were 
detected and photographed under UV light. Gel pictures were stored as .tif files for 
further analysis. GelCompare II software (Applied Maths, Sint-Martens-Latem, 
Belgium) was used to analyze and compare the banding patterns. The Unweighted 
Pair Group Method with Arithmetic Mean (UPGMA) tree graphically showing the 
level of relatedness between the isolates was created based on the Dice similarity 
coefficient (SD) (with a 1.5% position tolerance). Strains were considered to belong 





defined by ≥90% pattern similarities. 
2.6.2 Multi-locus Sequence Typing (MLST)  
The seven housekeeping genes of E. coli (adk, fumC, gyrB, icd, mdh, purA, 
recA), K. pneumoniae (gapA, infB, mdh, pgi, phoE, rpoB, tonB) and E. cloaceae 
(dnaA, fusA, gyrB, leuS, pyrG, rpIG, rpoB) were amplified by the primers shown in 
Table 6. For E. coli the MLST protocol of Wirth et al. was used [443]. The isolate 
was then assigned to sequence types using the tools on the E. coli MLST webpage 
(https://enterobase.warwick.ac.uk/species/ecoli/allele_st_search). For E. cloaceae, 
we used the MLST protocol of Miyoshi-Akiyama et al. [444]. Sequence types were 
established using E. cloaceae MLST webpage (http://pubmlst.org/ecloacae/). While 
for K. pneumoniae the protocol of Diancourt et al. [296] was applied and K. 
pneumoniae MLST webpage (https://bigsdb.pasteur.fr/klebsiella/klebsiella.html) was 








Table 6: PCR programs and primers used for E. coli, E. cloaceae and K. pneumoniae MLSTs 
Gene 
targeted 









E. coli MLST(Wirth et al. 2006) [443] 
adk adk F ATTCTGCTTGGCGCTCCGGG 
583bp 
5 minutes at 
94°C 
35X (60” at 
94°C, 60” at 





 adk R CCGTCAACTTTCGCGTATTT 
fumC fumC F TCACAGGTCGCCAGCGCTTC 
806 bp 
 fumC R GTACGCAGCGAAAAAGATTC 
gyrB gyrB F TCGGCGACACGGATGACGGC 
911 bp 
 gyrB R ATCAGGCCTTCACGCGCATC 
icd icd F ATGGAAAGTAAAGTAGTTGTTCCGGCACA 
878 bp 
 icd R GGACGCAGCAGGATCTGTT 
mdh mdh F ATGAAAGTCGCAGTCCTCGGCGCTGCTGGCGG 
932 bp 
 mdh R TTAACGAACTCCTGCCCCAGAGCGATATCTTTCTT 
purA purA F CGCGCTGATGAAAGAGATGA 
816 bp 
 purA R CATACGGTAAGCCACGCAGA  
recA recA F CGCATTCGCTTTACCCTGACC 
780 bp 























2’ at 95°C 
35X (15” at 
95°C, 10” at 
50°C and 60” at 
72°C) 
7’ at 72°C 
dnaA-r KGCCAGCGCCATCGCCATCTGACGCGG 
fusA fusA-f2 TCGCGTTCGTTAACAAAATGGACCGTAT 
906bp 
 fusA-r2 TCGCCAGACGGCCCAGAGCCAGACCCAT 
gyrB gyrB-F TCGACGAAGCGCTCGCGGGTCACTGTAA 
1153bp 
 gyrB-R GCAGAACCGCCCGCGGAGTCCCCTTCCA 
leuS leuS-f2 GATCARCTSCCGGTKATCCTGCCGGAAG 
845bp 
 leuS-r ATAGCCGCAATTGCGGTATTGAAGGTCT 
pyrG pyrG-f AYCCBGAYGTBATTGCRCAYMAGGCGAT 
535bp 
 pyrG-r GCRCGRATYTCVCCCTSHTCGTCCCAGC 
rplB rplB-f GTAAACCGACATCTCCGGGTCGTCGCCA 
746bp 
 rplB-r ACCTTTGGTCTGAACGCCCCACGGAGTT 
rpoB rpoB-f CCGAACCGTTCCGCGAACATCGCGCTGG 
944bp 
 rpoB-r2 CCAGCAGATCCAGGCTCAGCTCCATGTT 



















K. pneumoniae MLST (Diancourt et al.  2005)[296] 
rpoB VIC3 GGC GAA ATG GCW GAG AAC CA 
501bp 
5’ at 94°C 
35X (60” at 
94°C, 60” at 
50°C and 60” at 
72°C) 
10’ at 72°C 
 VIC2 GAG TCT TCG AAG TTG TAA CC 
gapA gapA173 TGA AAT ATG ACT CCA CTC ACG G 
450bp 
 gapA181 CTT CAG AAG CGG CTT TGA TGG CTT 
mdh mdh130 CCC AAC TCG CTT CAG GTT CAG 
477bp 
 mdh867 CCG TTT TTC CCC AGC AGC AG 
pgi pgi1F GAG AAA AAC CTG CCT GTA CTG CTG GC 
432bp 
 pgi1R CGC GCC ACG CTT TAT AGC GGT TAA T 
phoE phoE604.1 ACC TAC CGC AAC ACC GAC TTC TTC GG 
420bp 
 phoE604.2 TGA TCA GAA CTG GTA GGT GAT 
infB infB1F CTC GCT GCT GGA CTA TAT TCG 
318bp 
 infB1R CGC TTT CAG CTC AAG AAC TTC 
tonB tonB1F CTT TAT ACC TCG GTA CAT CAG GTT 
414bp 
 tonB2R ATT CGC CGG CTG RGC RGA GAG 
  





2.6.3 Sequencing  
PCR products were purified according to the manufacturer’s instruction with 
Wizard PCR and gel purification kit (Promega, USA) before sequencing. The 
sequencing was done using the Big Dye Cycle Terminator V.3.1 (Applied 
Biosystems). Using the 3130X Genetic Analyzer (Applied Biosystems) samples were 
sequenced in both directions then analyzed using the MEGA7 
(http://www.megasoftware.net/mega7/mega.html) and Clone Manager v9 (Scientific 
and educational software).  
2.6.4 Plasmid profile analysis 
For routine detection and isolation of large and small plasmids, the method of 
Kado and Liu [445] was used with slight adjustments. Bacterial cells were collected 
from an area of approximately 4 cm2 of overnight confluent culture on TSA at 37°C. 
Cells were suspended gently into 250 µl of lysing solution (3% SDS, 50 mM Tris, 
pH 12.57), and mixed thoroughly by gentle agitation until having a homogenous and 
viscous suspension, which was incubated for 45 minutes at 60°C with gentle mix 
every 15 minutes. After the incubation period, 250 µl of 1:1 phenol- chloroform was 
added. Emulsification of the solution was achieved by gentle shaking. The emulsion 
was separated by centrifugation at 13,000 rpm for 15 minutes. The top aqueous layer 
was transferred to clean tubes without disrupting the precipitate at the interface. 
Electrophoresis of the samples for 3 hours at 120 Volt in 0.8% agarose gel was done. 
The gels was stained with ethidium bromide, destained with 400 ml sterile MilliQ 






2.6.5 Southern blot and hybridization  
Plasmid gels prepared by the above method [445] were stained by ethidium 
bromide, photographed and scanned using the Biometra gel documentation system 
with rulers placed around the gel for further identification of bands.  
Gels were depurinated in 0.25 M HCl, followed by denaturation in 0.5 M 
NaOH, 1 M NaCl and finally neutralized in 1 M Tris, 0.6 M NaCl. All treatment 
steps were 15 minutes long at room temperature with gentle shaking and were 
repeated twice. Between each step; gels were rinsed in sterile distilled water. The 
gels were capillary-transferred to Hybond N+ membranes (Roche) by soaking 
overnight in 20X SSC (Saline Sodium citrate). The following day the membranes 
were UV cross-linked at 70000 micro-joules.  
Hybridization probes were made by PCR amplification of respective control 
strain for the following genes : blaNDM-1[437], blaOXA-48 [436], IncX3 [409] and parA 
gene of the IncL/M plasmid [215]; this was followed by DNA purification using 
Wizard SV Gel and PCR clean up system kit (Promega, USA) and quantification 
using the ND-1000 spectrophotometer (Nano Drop Technologies, USA). The DNA 
fragments were labeled using the DIG DNA labeling kit (Roche). Briefly, 200 ng of 
purified fragment were boiled for 10 minutes in a boiling water bath and rapidly 
chilled on ice. Then the denatured DNA was conjugated with digoxigenin according 
to the manufacturer’s instructions. Membranes were pre-hybridized at optimal 
hybridization temperature, calculated based on the size of the probe and GC ratio 
using the formula suggested by the manufacturer (Topt.=Tm-20
 °C with 
Tm=49.82+0.41(%G+C)-600/L (L=length of the probe in base pairs)), in a pre- 





sarcosine, 0.02% SDS) for 30 minutes followed by the addition of the hybridization 
buffer containing the probe. For post hybridization the blots were washed twice with 
2X SSC / 0.1% SDS (Sigma) at room temperature for 5 minutes with gentle shaking 
followed by two successive washings in 0.1X SSC / 0.1 % SDS at 68°C for 15 
minutes also with constant agitation. The membranes were briefly rinsed in washing 
buffer at room temperature, incubated in blocking solution for 30 minutes, and again 
incubated in antibody solution provided with the kit for 30 minutes. The blots were 
washed twice in washing buffer, equilibrated in detection buffer and finally 
incubated in the color substrate solution without shaking for various lengths of times 
in the dark till the desired spot or band intensity was visualized. The reaction was 
stopped using TE buffer (10mM Tris:1mM EDTA pH8 (Sigma)). The blots were 
digitized using the Biometra gel documentation system. In order to re-probe the 
membrane it was stripped with dimethyl formamide at 56°C followed by steps 
starting from the pre- hybridization.  
2.7  Screening for the presence of IncX3 incompatibility type plasmids  
Genomic DNA of isolates was subjected to PCR targeting the replicase of 
IncX3 incompatibility type plasmids as described [409], using primers IncX3-f – 
GTTTTCTCCACGCCCTTGTTCA and IncX3-r–CTTTGTGCTTGGCTATCATAA. 
The cycling conditions were as follows: initial denaturation for 5 min at 95°C, 
followed by 30 cycles 60 sec at 95°C, 30sec at 52°C and 60sec at 72°C, with a final 






2.8  PCR Based Replicon Typing (PBRT) 
In order to identify plasmid incompatibility types, PCRs were performed 
using primers of the original PBRT scheme [371], and also others targetting IncHI1B 
and IncL/M-OXA-48 type plasmids [215, 319]. Primers and conditions used for 
these two latter types of plasmids are listed in Table 7.  
DNA prepared of single plasmids containing derivatives was used as a 









Table 7: Primers and PCR conditions used for targeting IncHI1B and IncL/M-OXA-48 type plasmids. 





Cycle Final extension 
IncHI1B PCR (Dortet et al. 2012) [319] 
IncHI1B-Fw CAA AAC AGA GAG TAT TCA ACC C  
600 5’ at 94°C 
30 X (60” at 94°C, 30” at 
52°C , 60” at 72°C) 
5’ at 72°C 
IncHI1B-Rv CTG ATT CTT TTC GAG ACA GGG 
Amplification of repA, traU, parA genes located on IncL/M plasmid (Poirel et al. 2012) [215] 
RepA-A GACATTGAGTCAGTAGAAGG 
925 
5’ at 94°C 
35X (60” at 94°C, 60” at 
51°C, 60” at 72°C) 
















2.9  Plasmid transfer experiments  
2.9.1 Conjugation  
For conjugation experiments, E. coli J53RAZ (Na-azid resistant in-house 
derivative of the rifampin resistant J53 E. coli K-12) was used as recipient. 
Conjugation was attempted as follows: In a sterile 50 ml Falcon Tube (BD), log 
phase TSB cultures of the donor and recipient were combined in 1: 4 ratio in a 4 ml 
final volume. The mixture was incubated without shaking for an additional 4 hours, 
then it was centrifuged at 3500 rpm for 15 minutes. After resuspending the pellet in 
200 μl TSB, 100 μl of suspension was added as a drop to the middle of a TSA plate 
without any antibiotics (two plates were prepared), incubated overnight at 37°C. On 
the following day, the growth was collected in 5 ml 1X PBS, centrifuged and washed 
once in 1X PBS, followed by resuspension of the pellet in 3 ml of PBS. This 
suspension was serially diluted and plated onto plates having 100 μg/ml Na-azide 
and either 8 mg/L ceftazidime for NDM-producer wild-type isolates, or 0.25 mg/L 
ertapenem for OXA-48-like-producer wild-type isolates and incubated overnight at 
37°C. Next day single colonies were picked and subjected to plasmid electrophoresis 
and PCR. 
2.9.2 Transformation 
If we were unable to mobilize a specific plasmid into an E. coli J53RAZ by 
conjugation; transformation of the plasmid was attempted. For these experiments 
competent cells of E. coli DH5α, or E. coli GM2163 were used as a recipient.  
2.9.2.1 Competent cells preparation 
Cells were made competent by the following method: E. coli DH5α, or E. coli 





inoculate 500 ml Luria-Bertani broth and incubated at 37°C in shaken culture until 
OD600 reached 0.5-0.7 (2-4 hours). The culture was centrifuged at 5000 rpm for 10 
min at 4°C. Pellet was resuspended in 50 ml ice-cold 50mM CaCl
2 on ice and 
centrifuged at 5000 rpm for 5 min at 4°C. The pellet was then resuspnded in 50 ml 
ice-cold 50mM CaCl2 and left on ice for 20 minutes. The suspension was centrifuged 
at 5000 rpm for 10 min at 4°C. The pellet was resuspended in 25 ml of freezing 
solution of (50mM CaCl2 containing 20% glycerol), aliquoted in 150μl and snap 
freezed in liquid Nitrogen. Aliquots were stored at -80°C.  
2.9.2.2 Heat-shock transformation  
One μg of plasmid DNA purified from the wild type strain using Qiagen 
plasmid Maxi prep kit was used for transformation. The DNA was mixed with one 
aliquot (150μl) of competent cells, and the mixture was kept on ice for 20 minutes, 
followed by a heat shock at 42°C for 5 minutes in a thermoblock, with a final 
incubation on ice for 2 minutes. The transformation mixture was incubated for 1 hour 
at 37°C with shaking, and spread on plates containing either 8 mg/L ceftazidime for 
NDM-producer wild-type isolates or 0.25 mg/L ertapenem for OXA-48-like-
producer wild-type isolates and incubated overnight at 37°C. Next day single 
colonies were picked and subjected to plasmid electrophoresis and PCR. 
2.9.3 Plasmid purification  
Plasmids were extracted and purified using Qiagen plasmid Maxi kit (Qiagen, 
Germany). Briefly, 100 mL of Luria Bertani broth was inoculated and incubated for 
12-16 hour at 37°C with vigorous shaking. Cells were harvested by centrifugation at 
4°C at 6000 x g for 15 min. The pellet was re-suspended in 10 ml of Buffer P1 that 





immediately by vigorously inverting the tube 4–6 times then incubated at room 
temperature for 5 min. After adding 10 ml of chilled Buffer P3 and mixing 
vigorously, suspensions were incubated on ice for 20 min, followed by centrifugation 
at ≥20,000 x g for 30 min at 4°C. Meanwhile, the Qiagen column was equilibrated 
with 10 ml of Buffer QBT and allowed to empty by gravity flow. Supernatant 
containing plasmid DNA was added into the Qiagen column Qiagen-tip 100, allowed 
to enter the resin by gravity flow. The Qiagen column was washed twice with 30 ml 
Buffer QC, and the DNA was eluted with 15 ml Buffer QF. In order to precipitate 
DNA, 10.5 ml room-temperature isopropanol was added to the eluted DNA, mixed 
and centrifuged immediately at 4000 x g for 75 min at 4°C. 5 ml room-temperature 
70% ethanol was added to the DNA pellet, followed by centrifugation at 4000 x g for 
30 minutes. The pellet was air-dried. The DNA was dissolved in nuclease free water.  
DNA concentration and quality were assessed using the ND-1000 spectrophotometer 
(Nano Drop Technologies, USA), and were also analyzed by agarose gel 
electrophoresis. 
2.9.4 Establishing the complete plasmid sequences  
Plasmid DNA purified of single plasmid containing transconjugants or 
transformants (TF) were sent for commercial next generation sequencing on the 
Illumina MiSeq platform (performed at the CCIB DNA Core Facility in 
Massachusetts General Hospital (Cambridge, MA)). The gaps between contigs 
assembled were closed by PCR and by direct sequencing of the amplicons. The 
complete plasmid sequences were assembled with Clone Manager v9.0 (Sci-Ed 





Auckland, New Zealand) and Sequin (http://www.ncbi.nlm.nih.gov/Sequin), and 
submitted to GenBank.  
2.9.5 Phylogenetic analysis of the conserved regions of plasmids 
Regions of plasmid backbone sequences present in each plasmid were aligned 
using ClustalW. Phylogenetic (Neighbor-Joining) tree was constructed using the 
Jukes-Cantor genetic distance model with 500 bootstrap replicates. Missing data 
were ignored. For this analysis Geneious R11.0.4 software (Biomatters Ltd., 
Auckland, New Zealand) was used. 
2.10 Whole genome sequencing 
2.10.1 Genomic DNA extraction for whole genome sequencing by Illumina   
MiSeq 
Genomic DNA was isolated using Wizard genomic DNA Purification kit 
(Promega, USA) as per the manufacturer’s instructions. Briefly: 1.5 mL of overnight 
culture in TSB was centrifuged at 14800 rpm for 3 minutes, the pellet was 
resuspended gently with 600µl of Nuclei Lysis Solution, and the mixture was 
incubated at 80°C for 5 minutes to lyse the cells; then cooled to room temperature. 
3µl of RNase Solution was added to the cell lysate, mixed and incubated at 37°C for 
45 minutes. 200µl of Protein Precipitation Solution was added to the sample after 
cooling to room temperature, vortexed, and incubated on ice for 5 minutes. Sample 
was then centrifuged for 3 minutes at 14800 rpm, the supernatant containing the 
DNA was transferred to a clean Eppendorf tube containing 600µl of room 
temperature isopropanol, mixed by inverting, and centrifuged for 3 minutes at 14800 
rpm. The pellet was washed with 600µl of room temperature 70% ethanol and 





air-dried. The DNA was dissolved in nuclease free water.  DNA concentration and 
quality was assessed using the ND-1000 spectrophotometer (Nano Drop 
Technologies, USA), and was also analyzed by agarose gel electrophoresis. 
2.10.2 Nextera XT DNA library preparation 
Qubit dsDNA BR Assay system was used for quantitation of the input 
bacterial genomic DNA (gDNA) as follows:  A mixture of 2 μl of each DNA sample 
+ 198 μl of the Qubit working solution was prepared for sample quantification. UV 
absorbance was then used to assess the DNA Quality. 
Bacterial DNA libraries were prepared using the Illumina Nextera®XT DNA 
Library Preparation Kit (Illumina, USA). An accurate quantified amount of 0.2 ng/μl 
input bacterial gDNA of the samples were used. 
First tagmentation of input bacteria gDNA was performed i.e. gDNA was 
fragmented and tagged with adaptor sequences to the ends using the Nextera XT 
transposome. Briefly, this was achieved by addition of 10 μl Tagment DNA buffer 
(TD) to each well of the 96-well Nextera XT Tagment Amplicon Plate (NTA) then 5 
μl gDNA of each sample were added (calculated at 0.2 ng/μl ‘1 ng total’) to their 
assigned well in the NTA plate. This was followed by additing 5 μl of Amplicon 
Tagment Mix to each well of the NTA plate. Sealing and centrifuging the NTA plate 
at 280 x g for 1 minute at 20°C was done, and then it was placed in the thermocycler 
with the following program: “55°C for 5 minutes - Hold at 10°C”. Five μl NT Buffer 
was then added to each well and the NTA plate was sealed and centrifuged again at 





Second, PCR amplification of the tagmented DNA while the addition of 
index 1 (i7) and index 2 (i5) for cluster formation. This was achieved as follows; 15 
μl Nextera PCR Master Mix were added to each well of the NTA plate and the 
arrangement of the index primers (i5 and i7) in the TruSeq Index Plate Fixture was 
done according to the manufacturer recommendations. Using a multi-channel pipette, 
5 μl index 2 primers were added to each column in the NTA plate while 5 μl index 1 
primers were added to each row of the NTA plate. Finally the NTA plate was sealed 
and centrifuged at 280 x g for 1 minute at 20°C. 
PCR using the following program was implemented: 72°C for 3 minutes, 
95°C for 30 seconds; 12 cycles of : 95°C for 10 seconds / 55°C for 30 seconds / 72°C 
for 30 seconds / 72°C for 5 minutes; Hold at 10°C. 
Third, the PCR cleanup step was performed to purify the library DNA using 
AMPure XP beads. Using a multi-channel pipette, PCR products from the NTA plate 
were transferred to a new labelled Clean Amplified plate (CAA). This was followed 
by the addition of 30 μl AMPure XP beads to each well of the CAA,  then the plate 
was incubated at room temperature for 5 minutes, after that the CAA plate was 
transferred to the magnetic stand and was left for two minutes (until the supernatant 
has been cleared); the supernatant was then removed and discarded. The beads were 
then washed twice with freshly prepared 80% ethanol at which 200 μl 80% ethanol 
were added to each sample, followed by incubating the plate on the magnetic stand 
for 30 seconds and finally removing and discarding the supernatant.  
After removal of the CAA plate from the magnetic stand, 52.5 μl 
resuspension buffer were added to each well and then the plate was left at room 





for two minutes (until the supernatant has been cleared). Then 50 μl of the 
supernatant from the CAA plate were transferred to a new labelled NTA plate.  
Library normalization step was performed to ensure an equal representation 
of the library in the pooled samples.  20 μl of the supernatant taken earlier were 
transferred to a new labelled Library Normalization Plate (LNP).  A mixture was 
prepared using Library Normalization Additives 1 (LNA1) together with Library 
Normalization Beads (1LNB1) as recommended by the supplier then 45 μl combined 
LNA1/LNB1 were added to each well of the LNP containing libraries then the plate 
was placed on microplate shaker set at 1800 rpm for 30 minutes.  LNP was then 
transferred to a magnetic stand and left for two minutes until the supernatant was 
cleared, supernatant was then removed and discarded. Washing each sample well 
twice, using 45 μl LN Wash1. The plate was then transferred to a magnetic stand and 
left for two minutes until the supernatant was cleared, supernatant was then removed 
and discarded in an appropriate hazardous waste container. For elution, a fresh stock 
solution of 30 μl 0.1 N NaOH were added to each well, the plate was then placed on 
shaker for 5 minutes at 1800 rpm. The LNP was then placed on the magnetic stand 
for two minutes until the liquid was cleared.  30 μl from the supernatant were 
transferred from the LNP plate to a new labelled storage plate (SGP) where 30 μl LN 
Storage buffer 1 were added to each well. Sealing and centrifugation of the SGP for 
1 minute at 1000 x g was done.   
Library Pooling and MiSeq Sample Loading where equal volumes (5 μl) of 
the normalized library were combined into a fresh Eppendorf tube then diluted by 
hybridization buffer; this was followed by heat denaturing (at 96°C for 2 minutes) 





reagent cartridge into the Load Samples reservoir. Sequence of the library was 
performed as indicated in the MiSeq System User Guide.  
Illumina sequencing was performed to result in paired end 250 bp reads in the 
sequencing facility of New York University, Abu Dhabi.  
2.10.3 Analysis of bacterial whole genome sequences. 
Illumina paired end 250 bp reads in fastq format were assembled using 
Velvet 1.1.04. MLST and cgMLST of strains was established and the minimum 
spanning tree was build using RidomTM SeqSphere+. The assembled reads were 
uploaded to the pathogen watch web based service (https://pathogen.watch) for the 
analysis by Kleborate for the virulence gene and capsule locus related information 
[55, 446].  
Similarly, for the detection of acquired resistance genes the assembled 
contigs were uploaded to the ResFinder website (https://cge.cbs.dtu.dk//services/ResFinder/) 
[447]. 
In case the Velvet assembly lacked an expected carbapenemase gene, the 
respective reads were uploaded to the Center of Genomic Epidemiology website for 
assembly using SPAdes 3.9 (https://cge.cbs.dtu.dk/services/SPAdes/) and the contigs 
produced were re-analyzed in the ResFinder. 
2.11 Statistical analysis 
Two-tailed Fisher's exact test was used to compare categorical variables of 
different groups of isolates, while in the case of continuous variables the unpaired t-





The normal distribution of age was confirmed by calculating the Skewness 
and Kurtosis values for each data sets. p values ≤0.05 were considered statistically 
significant.  
2.12 Ethical approval 
For samples collected from Dubai hospitals ethical approval was obtained 
from the Dubai Scientific Research Ethics Committee of Dubai Health Authority 
with the reference code DSREC-11.  
Studying the role of IncX3 plasmids and the K. pneumoniae ST4 clone in the 
emergence of CRE in the UAE involved previously established collections of strains 






Chapter 3: Results 
 
3.1 Carbapenemase carrying IncX3 plasmids in the United Arab Emirates 
3.1.1 Characteristics of carbapenemase producing Enterobacteriaceae harboring 
IncX3 type plasmids 
Of the 334 non-repeat carbapenem resistant Enterobacteriaceae (CRE) 
isolated between April 2009 and December 2014 from 12 hospitals of the UAE 
(Figure 4) screening for the IncX3 type by PCR identified 32 strains carrying IncX3 
plasmids, i.e. 13 Escherichia coli, 15 Klebsiella pneumoniae, 2 Enterobacter cloacae 
and one Citrobacter freundii and one Morganella morganii, respectively. The 
distribution of IncX3 plasmids among strains with various carbapenem resistance 
mechanisms is shown in Table 8. Two K. pneumoniae carrying IncX3 plasmids did 
not produce any carbapenemase.  
 
 
Figure 4: Geographical location of the 12 hospitals where 334 CRE were collected 
 
 
Hospital without IncX3 





Table 8: Distribution of IncX3 plasmid carrying isolates among strains expressing 




Detected Not detected 
Non carbapenemase-producer [n, (%)] 2 (5.1) 37 (94.9) 39 
Carbapenemase-producer [n, (%)] 30 (10.2) 265 (89.8) 295 
KPC 2 -  
NDM 18 71  
OXA-48-like 6 120  
NDM and OXA-48-like 4 71  
VIM 0 3  
Total 32 302 334 
 
In all the 30 carbapenemase producer Enterobacteriaceae (CPE) strains, the 
respective carbapenemase genes, in case of the double carbapenemase producers the 
blaNDM gene, were located on the IncX3 plasmid. Altogether 22 IncX3 plasmids 
carried blaNDM (13 NDM-1, 1 NDM-4, 6 NDM-5 and 2 NDM-7), 6 contained  
blaOXA-181 and 2 harbored blaKPC-2. The characteristics of these strains and their 
respective IncX3 plasmids are shown in Table 9. 
Some clonal clustering among the strains was encountered. The 13 E. coli 
strains represented 8 sequence types, of which only two contained more than 2 
strains. All members of one of these clusters (ST410) produced OXA-181, while 
single members of the ST167 cluster produced OXA-181, NDM-7 or NDM-5. 
The 13 K. pneumoniae strains were divided into 6 sequence types, of which a 
cluster of 5 K. pneumoniae ST11 strains produced NDM-1 and were isolated over a 
three years period of time from the same hospital. Also, a triplet of ST1318 





All IncX3 positive carbapenemase producer isolates were non-susceptible to 
at least one carbapenem. Resistance to 3rd generation cephalosporins, aztreonam, 
aminoglycosides, ciprofloxacin, co-trimoxasole, tetracycline, tigecycline, colistin and 
















Hospital Specimen Species 
Carbapenemase 
produced 
MLST Name Size (bp) Resistance gene(s)  
GenBank 
Acc. No 
ABC133 12/14/2012 TH sputum E.coli NDM-7 ST4108 pABC133-NDM 37070  blaNDM-7 KX214671* 
ABC239 8/15/2013 RH urine E.coli OXA-181 ST410 pABC239-OXA-181 51479  blaOXA-181 + qnrS1 MK412916 
ABC264 6/9/2014 TH unknown E.coli OXA-181 ST410 pABC264-OXA-181 51479  blaOXA-181 + qnrS1 MK412917 
ABC356 8/8/2014 MH urine E.coli OXA-181 ST410 pABC356-OXA-181 51479  blaOXA-181 + qnrS1 MK412918 
ABC381 11/4/2014 AAH rectal swab E.coli OXA-181 ST167 pABC381-OXA-181 51479  blaOXA-181 + qnrS1 MK412919 
ABC218 12/25/2012 RH wound E.coli NDM-7 ST167 pABC218-NDM 34403  blaNDM-7 KX214670* 
ABC233 7/21/2013 RH urine E.coli NDM-5 ST167 pABC233-NDM-5 46161  blaNDM-5 MK372390 
ABC384 11/5/2014 AAH urine E.coli NDM-5 ST1284 pABC384-NDM-5 46161  blaNDM-5 MK372389 
ABC54 1/2/2011 TH urine E.coli NDM-1 ST2206 pABC54-NDM-1 53023  blaNDM-1 + blaSHV-12 MK372382 
BC-13-836 9/24/2013 TH blood E.coli NDM-1 ST446 pBC836-NDM-1 52565  blaNDM-1 + blaSHV-11 MK372387 
ABC280 7/15/2014 TH urine E.coli NDM-5 ST448 pABC280-NDM5 35502  blaNDM-5 MK372392 
ABC286 8/15/2014 TH blood E.coli NDM-5 ST448  NT  NT  NT  NT 
ABC268 6/11/2014 AAH urine E.coli NDM-5 ST2083 pABC268-NDM-5 45232  blaNDM-5 MK372391 
ABC40 10/27/2009 TH wound E. cloacae NDM-1 ST417 pABC40-NDM-1 54035  blaNDM-1 + blaSHV-12 MK372380 
ABC302 2/26/2014 MH urine E. cloacae NDM-4 ST200 ABC302-NDM-4 49402  blaNDM-4 MK372388 
BC-13-947 7/11/2013 TH blood K. pneumoniae OXA-181 ST2095 pBC947-OXA-181 51479  blaOXA-181 + qnrS1 MK412920 
ABC260 3/31/2014 TH rectal swab K. pneumoniae OXA-181 ST3545 pABC260-OXA-181 51480  blaOXA-181 + qnrS1 MK412915 
ABC369 9/23/2014 TH abdominal fluid K. pneumoniae NDM-5 + OXA-162 ST307 pABC369-NDM-5 45252  blaNDM-5 MK372393 
ABC137 1/14/2013 MH wound K. pneumoniae NDM-1 + OXA-48 ST1318 pABC137-NDM-1 53022  blaNDM-1 + blaSHV-12 MK372384 
ABC141 4/20/2013 MH unknown K. pneumoniae NDM-1 + OXA-48 ST1318 NT NT NT NT 
ABC155 6/5/2013 SKMC blood K. pneumoniae NDM-1 + OXA-48 ST1318 NT NT NT NT 
ABC220 10/5/2012 RH wound K. pneumoniae KPC-2 ST14 pABC220-KPC-2 46900  blaKPC-2 MK412914 
ABC224 3/17/2013 RH sputum K. pneumoniae KPC-2 ST14 NT NT NT NT 
ABC52 9/19/2010 TH sputum K. pneumoniae NDM-1 ST11 pABC52-NDM-1 52565  blaNDM-1 + blaSHV-12 MK372381 
ABC53 9/19/2010 TH sputum K. pneumoniae NDM-1 ST11 NT NT NT NT 
BC680 7/18/2012 TH blood K. pneumoniae NDM-1 ST11 NT NT NT NT 
BC700 7/24/2012 TH blood K. pneumoniae NDM-1 ST11 pBC700-NDM-1 52565  blaNDM-1 + blaSHV-11 MK372386 
BC-13-817 9/17/2013 TH blood K. pneumoniae NDM-1 ST11 NT NT NT NT 
ABC80 5/8/2011 TH urine 
Citrobacter 
freundii 
NDM-1 NA pABC80-NDM-1 53023  blaNDM-1 + blaSHV-12 MK372383 
ABC140 3/25/2013 MH perianal swab 
Morganella 
morganii 
NDM-1 NA pABC140-NDM-1 52591  blaNDM-1  MK372385 








Table 10: Minimum inhibitory concentration of different antibiotics against the clinical isolates of carbapenemase producing Enterobacteriaceae 




































































































































ABC220 KPC-2 WT 256 64 128 >128 >128 >128 64 256 16 >256 4 32 0.5 256 
GM3163(pABC220-KPC-2) KPC-2 TF 4 4 2 16 4 >128 ≤0.125 1 1 ≤0.5 ≤0.5 ≤0.5 ≤0.125 16 
ABC224 KPC-2 WT 256 64 128 >128 >128 >128 32 256 32 >256 4 32 0.5 128 
ABC140 NDM-1 WT 2 32 8 128 32 4 8 2 4 ≤0.5 16 >256 4 >512 
DH5α(pABC140-NDM-1) NDM-1 TF 0.5 2 ≤0.25 >128 64 32 ≤0.125 ≤0.5 2 ≤0.6 ≤0.5 ≤0.5 ≤0.125 ≤0.25 
ABC40 NDM-1 WT 32 16 16 >128 >128 >128 >64 128 4 ≤0.7 256 2 1 8 
J53RAZ(pABC40-NDM-1) NDM-1 TC 0.25 4 4 >128 64 32 ≤0.125 ≤0.5 ≤0.5 ≤0.8 ≤0.5 ≤0.5 ≤0.125 0.5 
ABC52 NDM-1 WT 64 32 64 >128 >128 >128 >64 >256 >256 >256 4 ≤0.5 1 4 
J53RAZ(pABC52-NDM-1) NDM-1 TC 1 4 8 >128 64 64 ≤0.125 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.125 1 
ABC53 NDM-1 WT 64 64 64 >128 >128 >128 >64 >256 >256 >256 4 ≤0.5 2 16 
ABC54 NDM-1 WT 8 16 16 >128 128 >128 0.25 1 4 >256 128 ≤0.5 0.25 0.5 
DH5α(pABC54-NDM-1) NDM-1 TF 0.25 4 4 >128 64 32 ≤0.125 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.125 0.5 
ABC80 NDM-1 WT 8 8 4 >128 128 >128 4 32 1 128 ≤0.5 ≤0.5 0.25 0.5 
J53RAZ(pABC80-NDM-1) NDM-1 TC 0.5 8 4 >128 64 32 ≤0.125 1 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.125 0.5 
BC680 NDM-1 WT 16 32 64 >128 >128 >128 >64 4 16 >256 2 ≤0.5 2 4 
BC700 NDM-1 WT 16 64 32 >128 >128 >128 >64 2 16 >256 2 ≤0.5 2 4 
J53RAZ(pBC700-NDM-1) NDM-1 TC 2 4 4 >128 64 ≤0.25 ≤0.125 1 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.125 0.5 
BC-13-817 NDM-1 WT 16 32 32 >128 >128 >128 >64 4 16 >256 2 ≤0.5 2 4 
BC-13-836 NDM-1 WT 4 16 16 >128 >128 ≤0.25 ≤0.125 2 4 ≤0.5 128 ≤0.5 ≤0.125 0.5 
DH5α(pBC836-NDM-1) NDM-1 TF 0.25 2 ≤0.25 >128 64 ≤0.25 ≤0.125 ≤0.5 1 ≤0.5 ≤0.5 ≤0.5 ≤0.125 ≤0.25 
ABC141 NDM-1 + OXA-48 WT 16 64 32 >128 >128 >128 >64 128 8 >256 >256 4 16 8 
ABC155 NDM-1 + OXA-48 WT >256 >128 >128 >128 >128 >128 4 128 4 >256 >256 ≤0.5 2 128 
ABC137 NDM-1+ OXA-48 WT 16 64 32 >128 >128 >128 4 128 4 >256 >256 ≤0.5 2 8 
J53RAZ(pABC137-NDM-1) NDM-1 TC 0.25 4 4 >128 64 32 ≤0.125 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.125 0.5 
ABC302 NDM-4 WT 128 64 128 >128 >128 >128 64 >256 >256 >256 8 ≤0.5 2 16 
DH5α(pABC302-NDM-4) NDM-4 TF 0.25 2 ≤0.25 >128 64 ≤0.25 ≤0.125 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.125 ≤0.25 
ABC233 NDM-5 WT 32 16 32 >128 >128 >128 >64 >256 >256 128 1 ≤0.5 ≤0.125 0.5 
DH5α(pABC233-NDM-5) NDM-5 TF 0.5 2 ≤0.25 >128 64 ≤0.25 ≤0.125 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.125 ≤0.25 
ABC268 NDM-5 WT 32 16 32 >128 >128 32 >64 64 4 256 1 ≤0.5 0.25 1 
DH5α(pABC268-NDM-5) NDM-5 TF 0.25 2 ≤0.25 >128 64 ≤0.25 ≤0.125 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.125 ≤0.25 








Table 10: Minimum inhibitory concentration of different antibiotics against the clinical isolates of carbapenemase producing Enterobacteriaceae 




































































































































ABC280 NDM-5 WT 32 16 16 >128 >128 >128 >64 64 8 >256 1 ≤0.5 0.25 1 
J53RAZ(pABC280-NDM-5) NDM-5 TC 0.5 4 8 >128 128 ≤0.25 ≤0.125 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.125 1 
ABC286 NDM-5 WT 64 8 32 >128 >128 >128 >64 32 4 256 1 ≤0.5 0.25 1 
ABC384 NDM-5 WT 64 128 32 >128 >128 >128 >64 64 8 256 >256 ≤0.5 ≤0.125 0.5 
J53RAZ(pABC384-NDM-5) NDM-5 TC 0.25 4 4 >128 64 ≤0.25 ≤0.125 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.125 1 
ABC369 NDM-5 + OXA-162 WT 4 8 8 >128 >128 >128 >64 256 >256 >256 4 ≤0.5 2 4 
DH5α(pABC369-NDM-5) NDM-5 TF 0.25 2 ≤0.25 >128 64 ≤0.25 ≤0.125 ≤0.5 1 ≤0.5 ≤0.5 ≤0.5 ≤0.125 ≤0.25 
ABC133ETP NDM-7 WT 128 128 128 >128 >128 64 >64 64 8 ≤0.5 >256 ≤0.5 0.25 0.5 
DH5α(pABC133-NDM) NDM-7 TF 1 4 2 >128 64 ≤0.25 ≤0.125 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.125 ≤0.25 
ABC218 NDM-7 WT 64 16 32 >128 >128 >128 >64 256 8 256 1 ≤0.5 ≤0.125 0.5 
J53RAZ(pABC218-NDM) NDM-7 TF 2 8 8 >128 128 ≤0.25 ≤0.125 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.125 1 
ABC239 OXA-181 WT 2 0.5 ≤0.25 >128 >128 >128 >64 128 8 >256 >256 ≤0.5 ≤0.125 0.5 
DH5α(pABC239-OXA-181) OXA-181 TF 0.5 ≤0.25 ≤0.25 ≤0.25 ≤0.25 ≤0.25 ≤0.125 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.125 ≤0.25 
ABC260 OXA-181 WT 128 64 32 2 2 0.5 16 1 1 >256 4 16 2 >512 
DH5α(pABC260-OXA-181) OXA-181 TF ≤0.125 ≤0.25 ≤0.25 ≤0.25 ≤0.25 ≤0.25 ≤0.125 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.125 ≤0.25 
ABC264 OXA-181 WT 2 1 ≤0.25 >128 >128 >128 >64 4 4 256 >256 ≤0.5 0.25 1 
DH5α(pABC264-OXA-181) OXA-181 TF ≤0.125 ≤0.25 ≤0.25 ≤0.25 ≤0.25 ≤0.25 ≤0.125 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.125 ≤0.25 
ABC356 OXA-181 WT 2 1 0.5 >128 >128 >128 >64 128 8 >256 >256 ≤0.5 0.25 0.5 
DH5α(pABC356-OXA-181) OXA-181 TF 0.25 ≤0.25 ≤0.25 ≤0.25 ≤0.25 ≤0.25 ≤0.125 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.125 ≤0.25 
ABC381 OXA-181 WT 16 8 8 >128 128 8 64 2 2 256 256 ≤0.5 0.25 ≤0.25 
DH5α(pABC381-OXA-181) OXA-181 TF ≤0.125 ≤0.25 ≤0.25 ≤0.25 ≤0.25 ≤0.25 ≤0.125 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.125 ≤0.25 
BC-13-947 OXA-181 WT ≤0.125 2 0.5 16 2 64 1 2 2 >256 1 8 0.25 16 
DH5α(pBC947-OXA-181) OXA-181 TF ≤0.125 ≤0.25 ≤0.25 ≤0.25 ≤0.25 ≤0.25 ≤0.125 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.125 ≤0.25 
DH5α none R ≤0.125 ≤0.25 ≤0.25 ≤0.25 ≤0.25 ≤0.25 ≤0.125 1 1 ≤0.5 ≤0.5 ≤0.5 ≤0.125 ≤0.25 
GM2163 none R ≤0.125 ≤0.25 ≤0.25 ≤0.25 ≤0.25 ≤0.25 ≤0.125 2 4 ≤0.5 ≤0.5 ≤0.5 ≤0.125 16 
J53Raz none R ≤0.125 ≤0.25 ≤0.25 ≤0.25 ≤0.25 ≤0.25 ≤0.125 1 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.125 0.5 





3.1.2 Analysis of the complete sequence of IncX3 plasmids  
Based on the type of carbapenemase produced, the MLST and plasmid profile 
similarities of the host strains (shown in the Appendix); 21 IncX3 plasmids were 
selected for further analysis.  
First, the complete sequences of these plasmids (Table 9) were compared to 
the sequences of IncX3 plasmids previously described from the UAE (pABC133-


































All the six blaOXA-181 carrying plasmids had identical genetic load region 
containing the carbapenemase gene and a qnrS1 quinolone resistance gene as well.  
Seven of the eight blaNDM-1 carrying plasmids also carried a blaSHV ESBL 
gene in the genetic load region: two the blaSHV-11, and five the blaSHV-12 allele, 
respectively. Both blaSHV alleles were present in an IS26 bracketed composite 
transposon. In pABC140-NDM-1, this structure contained a truncated Tn3 
transposase instead of the ESBL gene.  
IncX3 plasmids carrying NDM alleles other than blaNDM-1 did not harbor any 
other resistance genes. The genetic surroundings of blaNDM-4, blaNDM-5, and blaNDM-7 
between IS26 and IS5 were identical.  
In pABC220-KPC-2 the blaKPC-2 gene was located on a Tn4401b transposon, 
and no further resistance gene was carried by this plasmid. 
Regarding the conserved regions of the plasmids, they were very similar to 
each other, with the variable presence of the region between the hns and parA genes 
described earlier in IncX3 plasmids as part of the basic core structure [409]. Notably, 
this region was partially or completely missing in pABC280-NDM-5, pABC218-
NDM and pABC133-NDM. Therefore, when comparing the plasmid backbones of 
IncX3 plasmid sequences, we used a 24905 bp-long region from parB gene to parA 
gene (from position 1286 to 26190 in pABC218-NDM, Acc.No. KX214670). This 
region coded for plasmid replication, partitioning and mobilization.  
In order to assess the similarities of locally encountered IncX3 plasmids to 
those identified elsewhere, the above described backbone sequences of 23 UAE 





plasmids from different geographical regions deposited in the GenBank (listed in 
Table 11).  
Table 11: IncX3 plasmids (retrieved from GenBank in January 2019) from different 
geographical regions with unique backbone sequences and beta-lactamase genes 
carried 
Resistance genes Country Name GenBank Accession No 
blaKPC-2 Hong Kong pKPC-NY79 JX104759 
blaNDM-17 China pAD-19R KX833071 
blaNDM-4 Myanmar pM216_X3 AP018146 
blaNDM-4 Australia pJEG027 KM400601 
blaNDM-4 Czech Republic pEncl-922cz MG252892 
blaNDM-5 Czech Republic pEsco-5256cz MG252891 
blaNDM-5 India pNDM-MGR194 KF220657 
blaNDM-5 Hong Kong pNDM-HK2998 MH234508 
blaNDM-5 Hong Kong pNDM-HK2967 MH234509 
blaNDM-5 South Korea pCREC-591_4 CP024825 
blaNDM-7 South Korea pCREC-532_3 CP024833 
blaNDM-7 Oman pOM26-NDM KP776609 
blaNDM-7 Kuwait pKW53T-NDM KX214669 
blaNDM-7 Canada pKpN01-NDM-7 CP012990 
blaNDM-7 Myanmar pM110-X3 AP018141 
blaNDM-7 China pEC50-NDM-7 KX470735 
blaOXA-181 Italy pKP_BO_OXA-181 MG228426 
blaOXA-181, qnrS1 China pOXA-181 KP400525 
blaOXA-181, qnrS1 Switzerland pKS22 KT005457 
blaOXA-181, qnrS1 Germany pOXA-181-IHIT35346 KX894452 
blaOXA-181, qnrS1 South Korea pD6-OXA_1_1 MG702491 
blaOXA-181, qnrS1 Myanmar pM206-OXA181 AP018831 
blaOXA-181, qnrS1 Czech Republic pOXA181_29144 KX523903 
blaOXA-181, qnrS1 Lebanon pSTIB_IncX3_OXA_181 MG570092 
blaOXA-181, qnrS1 Denmark pAMA1167-OXA-181 CP024806 
blaSHV-11 Italy pIncX-SHV JN247852 
blaSHV-11, blaKPC-3 Italy p45-IncX3 KT362706 
blaSHV-12 Netherlands pEC-393 KX618697 
blaSHV-12 Netherlands pEC-125 KX618703 
blaSHV-12, aac(6')-Ib USA pKPN-819 CP008799 
blaSHV-12, blaKPC-2 France pKpS90 JX461340 
blaNDM-1 + blaSHV-12 China pNDM-HN380 JX104760 
blaNDM-1 + blaSHV-12 Hong Kong pNDM-HK3694 MH234505 
blaSHV-12, blaTEM-1, 
qnrS1 
Netherlands pEC-NRS18 KX618696 







 The Neighbor-Joining tree constructed using the Jukes-Cantor genetic 
distance model with 500 bootstrap replicates of the 58 IncX3 plasmids’ backbone 
sequences aligned using ClustalW, depicting the relationship between these plasmid 
backbones and the evolutionary history inferred is presented in Figure 6. 
The comparison shows three distinct clades: one with blaNDM-1, blaNDM-4 and 
blaNDM-7 carrying plasmids from the UAE and with plasmids carrying similar 
carbapenemase genes not only from different countries of the Middle-East and Asia, 
but also with blaNDM-7 carrying plasmid from Canada and blaSHV-12  carrying plasmid 
from the Netherlands. blaNDM-5 carrying plasmids formed a distinct clade. blaOXA-181 
carrying IncX3 plasmids originating from various parts of the world formed another 
distinct clade with a single outlier (MG228426) from Italy, only. Plasmids coding for 

















Figure 6: Phylogenetic tree of IncX3 plasmid backbones
Plasmid names printed in bold represent IncX3 plasmids from the UAE, for plasmids retrieved from GenBank the 
accession number, the beta-lactamase gene carried, and the country of isolation is shown.   
(AU Australia, US United States of America, IT Italy, MY Myanmar, CA Canada, KR South Korea, CN China, 
OM Oman, KW Kuwait, NL The Netherlands, HK Hong Kong, LB Lebanon, CH Switzerland, CZ Czech 





3.2 Characterization of carbapenem resistant Enterobacteriaceae isolated in 
2015-2016 in Dubai, United Arab Emirates 
3.2.1 The collection 
During the study period, i.e. between June 2015 and June 2016, of the 13025 
Enterobacteriacea isolates encountered in the participating hospitals 4.6% was 
identified as CRE, a feature being the most common (16.2%) among K. pneumoniae 
(Table 12).   








Klebsiella pneumoniae 2900 470 (16.2) 70 (14.9) 
Escherichia coli 8112 52 (0.6) 13 (25.0) 
Other Enterobacteriaceae 2013 81 (4.0) 6 (7.4) 
All 13025 603 (4.6) 89 (14.8) 
 
Of these, altogether 107 strains were submitted for the current study. Two 
strains were excluded for being carbapenem susceptible by the time of the 
confirmatory test and further 16 were omitted as they represented multiple isolates 
from same patients. The remaining 89 CRE strains (14.8% of all CRE isolated during 
the study period), i.e. 70 Klebsiella pneumoniae, 13 Escherichia coli, 3 Enterobacter 
cloacae, 2 Citrobacter sp. and one Serratia marcescens were subjected to further 








Table 13: General characteristics and distribution of various carbapenemases in 
different species of CRE studied 
Characteristics Enterobacteriaceae infections n (%) 












 <65 years 31 (34.8%) 9 14 4 4 
 65 58 (65.2%) 10 27 13 8 
Gender 
 Female 33 (37%) 10 12 4 7 
 Male 56 (63%) 9 29 13 5 
Ethnicity 
 UAE 31(34.8%) 5 14 7 5 
 Non-UAE national 44 (49.4%) 11 20 8 5 
 Unknown 14(15.7%) 3 7 2 2 
Hospital 
 Private 25 (28.1%) 8 10 3 4 
 Public 64 (72.9%) 11 31 14 8 
Sample source 
 Blood 7 (7.9%) 2 5 0 0 
 Respiratory 20 (22.5%) 1 12 6 1 
 Skin and soft tissue 17 (19%) 3 7 1 6 
 Urine 45 (50.6%) 13 17 10 5 
Organism 
 Escherichia coli 13 (14.6%) 2 7 0 4 
 Klebsiella 
pneumoniae 
70 (78.7%) 16 31 17 6 
 Enterobacter cloacae 3 (3.4%) 1 0 0 2 
 Citrobacter species 2 (2.2%) 0 2 0 0 
 Serratia marcescens 1 (1.1%) 0 1 0 0 
* confirmed with the carbaNP test 
 
The mcr-1, -2, -3 or -4 genes were not detected among the colistin resistant 
members of the pool. Eighty seven percent of the isolates produced carbapenemase, 
while 13% of them tested negative with the carbaNP test. blaIMP, blaVIM, and blaKPC 
genes were not identified in the 77 carbapenemase producer strains, whereas in 53% 





detected, respectively. The distribution of the carbapenemase genes detected in 
various species is shown in Table 13.  
3.2.2  Antibiotic susceptibility and the presence of antibiotic resistance genes 
The antibiotic susceptibilities, the MIC90 and MIC50 figures for K. 
pneumoniae and E. coli isolates, i.e. species for which these calculations were 
possible, are summarized in Table 14.  
Table 14: Antibiotic susceptibility of the CRE strains isolated in Dubai 
Organism (No tested) 
/antibiotic 
MIC (mg/L) % 
Susceptible 50% 90% 
All isolates (89) 
ampicillin >32 >32 0 
amoxicillin/clavulanate >32/16 >32/16 0 
piperacillin/ tazobactam >128/4 >128/4 0 
cefotaxime >64 >64 4.5 
ceftazidime >64 >64 9.0 
cefepime >64 >64 16.7 
aztreonam >128 >128 12.4 
ertapenem >64 >64 0 
imipenem >16 >16 21.3 
meropenem >16 >16 16.9 
amikacin 32 >64 46.1 
gentamicin 8 >16 43.8 
ciprofloxacin >4 >4 4.5 
nitrofurantoin 128 256 10.1 
trimethoprim/sulfamethoxazole >16/304 >16/304 18.0 
tigecycline ≤1 >8 61.8 
chloramphenicol 32 >256 29.2 
colistin ≤0.5 32 73 
XDR (%) 32.6 








Table 14: Antibiotic susceptibility of the CRE strains isolated in Dubai (continued) 





Klebsiella pneumoniae (70) 
ampicillin NA NA NA 
amoxicillin/clavulanate >32/16 >32/16 0 
piperacillin/ tazobactam >128/4 >128/4 0 
cefotaxime >64 >64 1.4 
ceftazidime >64 >64 8.6 
cefepime >64 >64 14.3 
aztreonam >128 >128 11.4 
ertapenem >64 >64 0 
imipenem >16 >16 15.7 
meropenem >16 >16 7.1 
amikacin 64 >64 35.7 
gentamicin 8 >16 45.7 
ciprofloxacin >4 >4 2.9 
nitrofurantoin 256 256 1.4 
trimethoprim/sulfamethoxazole >16/304 >16/304 12.9 
tigecycline ≤1 >8 57.1 
chloramphenicol 64 >256 20 
colistin ≤0.5 32 68.6 
XDR (%) 40 
PDR (%) 5.7 
Escherichia coli (13) 
ampicillin >32 >32 0 
amoxicillin/clavulanate >32/16 >32/16 0 
piperacillin/ tazobactam >128/4 >128/4 0 
cefotaxime >64 >64 15.4 
ceftazidime >64 >64 7.7 
cefepime >64 >64 30.8 
aztreonam >128 >128 15.4 
ertapenem >64 >64 0 
imipenem 2 >16 30.8 
meropenem 1 >16 53.8 
amikacin 4 >64 84.6 
gentamicin >16 >16 38.5 
ciprofloxacin >4 >4 0 
nitrofurantoin 64 256 53.8 
trimethoprim/sulfamethoxazole >16/304 >16/304 23.1 
tigecycline ≤1 ≤1 10 
chloramphenicol 8 256 76.9 
colistin ≤0.5 ≤0.5 100 
XDR (%) 0 






All strains were multi-drug resistant, of these 29 (32.6%) also qualified as 
extremely-drug resistant (XDR). All E. coli strains remained susceptible to 
tigecycline and colistin, and none of them were XDR. On the other hand, in K. 
pneumoniae the rate of XDR was 40%, the non-susceptibility to tigecycline was 
42.9%, and to colistin was as high as 31.4%, respectively. Four K. pneumoniae 
isolates did not show susceptibility to any of the antibiotics tested. The distribution 
of XDR and PDR isolates among various species is shown in Table 15.  










XDR (n) 24  1 0 0 0 25 




















3.2.3  Molecular typing  
Pulsed field gel electrophoresis confirmed the diversity of the E. coli, E. 
cloacae and Citrobacter sp. isolates (Figure 7-9).  
 
Figure 7: PFGE comparison of carbapenem resistant E. coli 
 











This was in sharp contrast with the clustering of K. pneumoniae isolates. In 
this species 35 strains (51.4% of the typable strains) exhibited PFGE patterns with 
>80% similarity (cluster PF-KP5). The remaining 33 strains grouped into 16 PFGE 
patterns with two 6-membered clusters, one triplet, five duplets and 8 unique patterns 
(Figure 10). Two K. pneumoniae were untypable by PFGE. 
Within cluster PF-KP5 six sub-clusters of >90% similarity, were identified. 
In each of them at least one strain of every unique carbapenemase gene patterns (i.e. 
carrying exclusively blaNDM or blaOXA48-like or both) were subjected to MLST. All 19 
strains selected belonged to K. pneumoniae ST14 (Figure 10). The sequence type of 
the four pan-drug resistant K. pneumoniae was also determined. Of those two, 
DHKp8 and DHKp26, i.e. strains from the PF-KP5 group, also belonged to ST14, 
while the two unrelated pan-drug resistant isolates, DHKp9 and DHKp34 exhibited 
sequence types ST15 and ST231, respectively. Furthermore, selected isolates having 
unique carbapenemases in the two 6-membered clusters were also MLST-ed. With 
the exception of the NDM and OXA-48-like co-producer K. pneumoniae ST1513 












Figure 10: PFGE comparison of carbapenem resistant Klebsiella pneumoniae 
Grey boxes indicate colistin resistant strains, * marks pan-drug resistant strains, bold rectangular box 
represent the ST-14 looking like isolates (PF-KP5) 
 
 















































































































































































































































































































































































































































































3.2.3.1 Features associated with the K. pneumoniae ST14 PF-KP5 group 
Strains belonging to this cluster were distributed among all participating 
hospitals. Analyzing their characteristics revealed that members of this ST14 clone 
were significantly more likely to be isolated from Emirati patients, to be amikacin 
non-susceptible, extremely drug resistant (XDR), and to co-produce OXA-48-like 
and NDM carbapenemases than isolates outside of this cluster (Table 16).  











Blood 1 3 0.6139 
Urine 19 18 1.0000 
Respiratory 12 5 0.0928 
Skin and soft tissue 3 9 0.1103 
Patients’ characteristics 
Mean age in years ±SD 70.9±12.8 66.5±15.1 0.2198* 
Male:female ratio 25:10 22:13 0.6113 




0 6 0.0248 
NDM and OXA-48-like 
co-producer 
16 1 0.0001 
Single OXA-48-like 
producer  
17 14 0.6307 




20 18 0.8106 
Amikacin non-susceptible 31 14 0.0001 
Tigecycline non-
susceptible 
15 15 1.0000 
Colistin resistant 13 9 0.4436 
XDR and PDR 19 9 0.0273 
*student t test 






All but one of the 17 NDM-OXA dual carbapenemease producers 
(94.4%), belonged to K. pneumoniae PF-KP5. Although colistin resistance was 
not significantly associated with this clone, it was more common within the 
cluster (37.1%) than in K. pneumoniae having different pulsotypes (27.3%).  
Furthermore, all colistin resistant K. pneumoniae outside of the PF-KP5 group 



















3.3 Characterization of K. pneumoniae ST14 strains isolated in the Arabian 
Peninsula 
Among 761 non-repeat carbapenem resistant Klebsiella pneumoniae (CRKP) 
isolated in June 2011- June 2016 from five cities in the UAE (Dubai, Abu Dhabi, 
Sharjah, Um Al Qwain, Al Ain) and from four other countries of the Arabian 
Peninsula (Kingdom of Saudi Arabia (KSA), Kuwait, Bahrain and Oman), we 
identified 172 K. pneumoniae exhibiting PFGE profiles with ≥80% similarity to 
known CRKP-ST14 (Figure 11).  The number of strains with PFGE patterns similar 
to CRKP-ST14 in each country is shown in Table 17. 
Table 17: Proportion of strains with PFGE patterns similar to CRKP-ST14 in 
different countries 
 
UAE KSA Kuwait Bahrain Oman All 


















  NDM-1 + OXA-232 
 
  NDM-1 
  NDM-1 + OXA-48  
 
  OXA-232 
  NDM-1 + OXA-162 
 
  OXA-162 
  KPC-2 
 
  No carbapenemase 
   
 ◄ Confirmed ST14  



















































































































































































































































































































































































































































































































































































































































Figure 11: PFGE comparison of 172 carbapenem-resistant Klebsiella pneumoniae 





The results of KPC-, NDM-, OXA-48-like, VIM-, IMP-carbapenemase 
alleles identified in the 172 K. pneumoniae are shown in Table 18. 
Table 18: Carbapenemase genes identified in the 172 CRKP exhibiting ST14 like 
PFGE patterns 
Carbapenemase allele N 
blaNDM-1  41 
blaNDM-1 and blaOXA-232 65 
blaNDM-1 and blaOXA-162 4 




No carbapenemase 1 
 
Within the 172 CRKP ST14-like isolates, 14 subgroups exhibiting ≥90% 
PFGE pattern similarity were formed. At least one isolate from each subgroup, or if 
they harboured different carbapenemases, one of each with non-identical 
carbapenemases were subjected to MLST (n=70), which proved that they indeed 
belonged to ST14 (Figure 11).  
To localize the carbapenemase genes in the CRKP-ST14 isolates, plasmid 
gels were hybridized with the respective probes. (All gel pictures and hybridization 
membranes are shown in the Appendix). The comparison of plasmid profiles with the 
schematic presentation of the plasmid hybridizing with the respective carbapenemase 
probes is shown in Figure 12. However, we were unable to localize the blaOXA-232 in 













Based on the alleles of the carbapenemase genes and the plasmid 
localizations of these genes, we formed 15 subgroups (SGs) of the 70 CRKP-ST14 as 
listed in Table 19. 
Table 19: Subgroups of CRKP-ST14 with various alleles of carbapenemases located 
on different size plasmids 
Subgroup N NDM allele NDM plasmid size OXA allele OXA plasmid size 
A 17 NDM-1 ≥240Kb OXA-232 ≈6Kb 
B 4 NDM-1 ≥240Kb OXA-48 ≈60Kb 
C 4 NDM-1 ≥240Kb OXA-162 ≈60Kb 
D 8 NDM-1 ≥240Kb none NA 
E 1 NDM-1 ≈120Kb OXA-232 ≈60Kb 
F 7 NDM-1 ≈120Kb OXA-232 ≈6Kb 
G 2 NDM-1 ≈120Kb none NA 
H 1 NDM-1 ≈120Kb OXA-232 
impossible to localize by 
hybridization 
I 5 none NA OXA-162 ≈60Kb 
J 1 none NA OXA-232 ≈10Kb 
K 15 none NA OXA-232 ≈6Kb 
L 1 none NA OXA-232 
impossible to localize by 
hybridization 





N 2 KPC-2 
O 1 Carbapenemase non-producer 
 
Of these isolates we selected minimum 4 representatives of each subgroups 











Table 20: Characteristics of strains subjected to whole genome sequencing 






A ABC127 2012 Blood AQH, Sharjah 5 
A ABC252 2014 Unknown ZMH, Abu Dhabi 5 
A ABC497 2015 Urine TH, Al Ain 5 
A DHKp21 2016 Urine DH, Dubai 5 
B SA121 2015 Unknown KFSH, Riyadh, KSA 14 
B SA165/S 2015 Unknown KFSH, Riyadh, KSA 14 
B SA166 2015 Unknown KFSH, Riyadh, KSA 14 
B SA176 2015 Unknown KFSH, Riyadh, KSA 14 
C ABC261 2014 
Perianal 
swab 
KH-Um Al Qwain 5 
C ABC645 2015 Urine SKMC, Abu Dhabi 5 
C ABC697 2014 
Perianal 
swab 
KH-Um Al Qwain 5 
C ABC703 2015 Wound KH-Um Al Qwain 5 
D ABC83 2011 
Nasal 
screen 
MH, Abu Dhabi 5 
D ABC131 2012 Rectal swab AQH, Sharjah 5 
D ABC139 2013 Sacral skin MH, Abu Dhabi 7 
D ABC273 2014 Sputum AAH, Al Ain 5 
D SA131 2015 Unknown KFSH, Riyadh, KSA 14 
E ABC240 2013 Blood RH, Dubai 5 
F ABC229 2013 Urine RH, Dubai 11 
F RH60 2016 Urine RH, Dubai 11 
F RH45 2016 Sputum RH, Dubai 8 
F DHKp14 2015 Sputum DH, Dubai 11 
G DHKp6 2015 Urine DH, Dubai 11 
G WHKp1 2014 Urine WC, Dubai 11 
H ABC241 2013 Sputum RH, Dubai 11 
I ABC681 2015 Urine SKMC, Abu Dhabi 1 
I MCH15 2016 Urine MCH, Dubai 13 
I DHKp10 2015 Sputum DH, Dubai 5 
I RH48 2016 Urine RH, Dubai 6 
I DHKp31 2016 Urine DH, Dubai 5 
J ABC232 2013 Wound RH, Dubai 4 
K ABC270 2014 Urine AAH, Al Ain 11 
K ABC716 2015 Blood ZMH, Abu Dhabi 10 
K BA1 2015 Blood BDF, Riffa, Bahrain 5 
K ABC375 2014 Rectal swab TH, Al Ain 5 
L ABC334 2014 Blood SKMC, Abu Dhabi 5 
M ABC643 2015 Urine SKMC, Abu Dhabi 12 
N ABC220 2012 Wound RH, Dubai 5 






The result of the Velvet assembly of the Illumina reads is summarized in 
Table 21.  



















ABC127 5809195 125 265 849538 46473 191826 99.5 
ABC131 5961443 232 221 524733 25695 173434 99.6 
ABC139 5889327 250 200 288472 23557 83557 98.4 
ABC220 5699694 171 225 324953 33331 158617 99.3 
ABC225 5642359 286 206 130827 19728 49230 98.9 
ABC229 5761817 563 209 307021 10234 60604 98.7 
ABC232 5860727 393 200 205328 14912 39841 98.6 
ABC240 5786071 213 200 393110 27164 97639 99.2 
ABC241 5693070 258 206 174151 22066 58851 98.6 
ABC252 5846567 156 209 512109 37477 191768 99.4 
ABC261 5956594 228 209 696470 26125 140697 99.3 
ABC270 5914488 194 204 382134 30487 157499 99.3 
ABC273 5815262 230 204 222781 25283 79005 98.2 
ABC334 5791551 244 202 173939 23735 64126 99.0 
ABC375 5851467 159 213 411735 36801 163126 99.3 
ABC497 5734851 159 253 387861 36068 130040 99.4 
ABC643 5787685 235 200 329878 24628 65791 98.4 
ABC645 5884874 357 206 162653 16484 40201 98.7 
ABC681 5789489 812 205 301084 7129 66565 98.9 
ABC697 5838890 308 200 249991 18957 49675 99.2 
ABC703 5922381 1128 201 164112 5250 38915 98.6 
ABC716 5647419 297 200 150240 19014 51873 98.4 
ABC83 5861041 162 262 849851 36179 231631 99.5 
BA1 5810838 326 202 162719 17824 38062 98.6 
DHKp10 5962056 698 201 165672 8541 39392 98.6 
DHKp14 5915588 1681 205 75275 3579 20264 96.1 
DHKp21 5665306 279 201 238917 20305 53745 98.9 
DHKp31 5734296 313 200 230361 18320 50506 98.8 
DHKp6 5702039 190 206 393204 30010 97105 98.1 
MCH15 5859798 269 200 221252 21783 64226 98.6 
RH45 5504435 219 202 213230 25134 75850 99.3 
RH48 5573400 457 201 150330 12195 39548 98.4 
RH60 5770882 445 200 120659 12968 28971 97.2 
SA121 6193334 1940 205 162670 3192 50257 98.4 
SA131 5765041 882 200 65483 6536 14475 94.7 
SA165-S 5762375 414 202 203167 13918 34431 98.3 
SA166 5890440 413 201 101901 14262 36261 98.6 
SA176 6273034 2278 205 114849 2753 26574 97.6 







Core genome MLST of the 39 isolates performed using Ridom TM 
SeqSphere+ software revealed three clusters that differed by up to 14 out of 2358 
alleles, and seven singletons. The minimum spanning tree (MST) based on the 








Figure 13: Minimum spanning tree based on cgMLST of CRKP-ST14 (color coded 






As it is shown in Figure 13 each cluster was comprised of strains having 
various carbapenemases. 
In Figure 14 the isolates in the MST were color coded based on the city of 
isolation, which demonstrates that isolates of Cluster 1 and Cluster 2 were recovered 
in multiple cities of the UAE and in Bahrain, and Cluster 3 contained the five isolates 





Figure 14: Minimum spanning tree based on cgMLST of CRKP-ST14 (color coded based 





Analysis of the assembled contigs using Kleborate (on 
https://pathogen.watch/) demonstrated that all but one CRKP-14 isolate harbored 
yersiniabactin on ICEKp5, and the sequence type of yersiniabactin was YbST140 or 
its single, double or triple locus variants with the exception of SA131 harboring 
double locus variants of YbST138 (Table 22). Other virulence genes (colibactin, 
aerobactin, salmochelin, rmpA and rmpA2) were not present in any of the isolates 
WGS-ed. The capsular locus variants were also tested by Kleborate, confirming the 
presence of KL2 in 26 isolates, and interestingly KL64 in 13 isolates tested. 
Comparing the capsular locus variations with the cgMLST clustering revealed that 
Cluster 2 and two singletons related closely to Cluster 2 harbored the KL64 variant 







Figure 15: Minimum spanning tree based on cgMLST of CRKP-ST14 (color coded 


























ABC127 A 5 C1 ybt 14  ICEKp5 140 wzi2 KL2 
ABC252 A 5 C1 ybt 14  ICEKp5 140 wzi2 KL2 
ABC497 A 5 C1 ybt 14  ICEKp5 140 wzi2 KL2 
DHKp21 A 5 C2 ybt 14  ICEKp5 140-2LV wzi64 KL64 
SA121 B 14 C3 ybt 14  ICEKp5 140-1LV wzi2 KL2 
SA165/S B 14 C3 ybt 14  ICEKp5 140-1LV wzi2 KL2 
SA166 B 14 C3 ybt 14  ICEKp5 140-1LV wzi2 KL2 
SA176 B 14 C3 ybt 14  ICEKp5 140-1LV wzi2 KL2 
ABC261 C 5 C1 ybt 14  ICEKp5 140 wzi2 KL2 
ABC645 C 5 C1 ybt 14  ICEKp5 140 wzi2 KL2 
ABC697 C 5 C1 ybt 14  ICEKp5 140 wzi2 KL2 
ABC703 C 5 C1 ybt 14  ICEKp5 140 wzi2 KL2 
ABC131 D 5 C1 ybt 14  ICEKp5 140 wzi2 KL2 
ABC139 D 7 C1 ybt 14  ICEKp5 140 wzi2 KL2 
ABC273 D 5 C2 ybt 14  ICEKp5 140-1LV wzi64 KL64 
ABC83 D 5 C1 ybt 14  ICEKp5 140 wzi2 KL2 
SA131 D 14 C3 ybt 14  ICEKp5 138-2LV wzi2 KL2 
ABC240 E 5 S5 ybt 14  ICEKp5 140 wzi2 KL2 
ABC229 F 11 C2 ybt 14  ICEKp5 140-2LV wzi64 KL64 
DHKp14 F 11 C2 ybt 14  ICEKp5 140-2LV wzi64 KL64 
RH45 F 8 C2 ybt 14  ICEKp5 140-3LV wzi64 KL64 
RH60 F 11 S6 ybt 14  ICEKp5 140-2LV wzi64 KL64 
DHKp6 G 11 C2 ybt 14  ICEKp5 140-2LV wzi64 KL64 
WHKp1 G 11 C2 ybt 14  ICEKp5 140-2LV wzi64 KL64 
ABC241 H 11 C2 ybt 14  ICEKp5 140-2LV wzi64 KL64 
ABC681 I 1 C1 - - - wzi2 KL2 
DHKp10 I 5 C1 ybt 14  ICEKp5 140-1LV wzi2 KL2 
DHKp31 I 5 C1 ybt 14  ICEKp5 140-1LV wzi2 KL2 
MCH15 I 13 C1 ybt 14  ICEKp5 140 wzi2 KL2 
RH48 I 6 C1 ybt 14  ICEKp5 140-1LV wzi2 KL2 
ABC232 J 4 S1 ybt 14  ICEKp5 140 wzi2 KL2 
ABC270 K 11 S2 ybt 14  ICEKp5 140 wzi2 KL2 
ABC375 K 5 C2 ybt 14  ICEKp5 140-1LV wzi64 KL64 
ABC716 K 10 C2 ybt 14  ICEKp5 140-2LV wzi64 KL64 
BA1 K 5 C2 ybt 14  ICEKp5 140-1LV wzi64 KL64 
ABC334 L 5 S7 ybt 14  ICEKp5 140-1LV wzi64 KL64 
ABC643 M 12 C1 ybt 14  ICEKp5 140 wzi2 KL2 
ABC220 N 5 S4 ybt 14  ICEKp5 140 wzi2 KL2 





As shown in Table 22, the only group of strains in which the cgMLST and 
PFGE grouping overlapped was Cluster 3 with the isolates from Riyadh. Members of 
other PFGE subgroups were exhibiting various cgMLST types. 
The contigs assembled with Velvet were also analyzed for the presence of 
acquired antibiotic resistance genes using ResFinder…………………………….. 
(https://cge.cbs.dtu.dk//services/ResFinder/) (Table 23).  In three isolates (RH45, 
DHKp14 and ABC241), the blaOXA-232 gene previously identified by PCR was not 
present in the Velvet assembly. Therefore, reads of these isolates were re-assembled 
using SPAdes 3.9 (https://cge.cbs.dtu.dk/services/SPAdes/). The SPAdes assembly 
confirmed the presence of blaOXA-232 gene in both RH45 and DHKp14. However, in 
ABC241, previously positive by PCR for blaOXA-232 but negative by hybridization, 
the WGS data assembled by either Velvet or SPAdes could not confirm the presence 
of this gene.  
The array of acquired antibiotic resistance genes was remarkable: blaCTX-M-15 
ESBL gene was present in all but two isolates; and beyond a wide variety of genes 
coding for aminoglycoside modifying enzymes, the ribosomal methylase armA was 








Table 23: Acquired antibiotic resistance genes of CRKP-14 isolates detected by ResFinder 
 






































































































































































































































Aminoglycoside resistance genes PMQR Macrolide Phenicol Co-trimoxazole













































































































C1 A ABC127 128 64 64 >128 >128 2 >64 256 >256 >256 8 >256 ≤0.5 2 64
C1 A ABC252 128 128 64 >128 >128 >128 >64 >256 >256 >256 16 >256 ≤0.5 8 32
C1 A ABC497 64 128 64 >128 >128 >128 >64 >256 >256 >256 4 >256 16 1 16
C2 A DHKP21 128 128 64 >128 >128 >128 >64 256 >256 >256 8 32 ≤0.5 2 32
C3 B SA121 128 128 128 >128 >128 >128 >64 >256 >256 >256 8 >256 64 1 32
C3 B SA165S 64 64 64 >128 >128 >128 >64 >256 >256 >256 8 >256 64 1 16
C3 B SA166 64 64 64 >128 >128 >128 >64 >256 >256 >256 8 >256 64 1 16
C3 B SA176 128 64 128 >128 >128 >128 >64 >256 >256 >256 8 >256 ≤0.5 2 64
C1 C ABC261 128 64 64 >128 >128 >128 >64 >256 >256 >256 8 >256 ≤0.5 2 64
C1 C ABC645 128 128 64 >128 >128 >128 >64 >256 >256 >256 8 256 32 4 32
C1 C ABC697 128 64 128 >128 >128 >128 >64 >256 >256 >256 8 >256 ≤0.5 2 64
C1 C ABC703 128 64 64 >128 >128 >128 >64 >256 >256 >256 8 256 ≤0.5 2 64
C1 D ABC131 64 64 64 >128 >128 >128 >64 >256 >256 >256 8 >256 ≤0.5 2 64
C1 D ABC139 128 64 64 >128 >128 >128 >64 >256 >256 >256 >256 >256 ≤0.5 4 64
C2 D ABC273 64 32 64 >128 >128 >128 >64 256 >256 >256 8 >256 ≤0.5 4 16
C1 D ABC83 256 64 64 >128 >128 >128 >64 >256 >256 >256 >256 >256 ≤0.5 4 32
C3 D SA131 64 64 64 >128 >128 >128 >64 >256 >256 >256 8 >256 ≤0.5 2 64
S5 E ABC240 128 128 128 >128 >128 >128 >64 256 16 >256 8 >256 ≤0.5 1 128
C2 F ABC229 128 128 128 >128 >128 >128 >64 256 >256 >256 4 32 4 0.5 32
C2 F DHKP14 128 128 128 >128 >128 >128 >64 256 >256 >256 8 64 ≤0.5 1 16
C2 F RH45 128 64 64 >128 >128 >128 >64 4 32 4 8 16 16 1 128
S6 F RH60 128 64 32 >128 >128 >128 >64 >256 >256 >256 8 32 ≤0.5 2 32
C2 G DHKP6 64 128 32 >128 >128 >128 64 >256 >256 >256 1 2 16 0.25 16
C2 G WHKP1 128 128 128 >128 >128 >128 >64 256 >256 >256 16 64 ≤0.5 2 16
C2 H ABC241 128 128 64 >128 >128 >128 >64 256 >256 >256 32 32 ≤0.5 8 32
C1 I ABC681 16 4 4 64 >128 >128 >64 256 >256 >256 4 64 16 2 32
C1 I DHKP10 16 16 8 >128 >128 >128 >64 2 4 >256 2 >256 ≤0.5 1 64
C1 I DHKP31 4 8 2 >128 >128 >128 32 >256 >256 >256 1 32 ≤0.5 0.25 32
C1 I MCH15 128 32 32 >128 >128 >128 >64 256 >256 >256 8 >256 4 2 64
C1 I RH48 64 16 8 >128 >128 >128 >64 128 16 4 8 256 ≤0.5 2 64
S1 J ABC232 64 8 16 >128 >128 >128 >64 >256 >256 >256 8 >256 ≤0.5 1 64
S2 K ABC270 128 16 16 >128 >128 >128 >64 128 16 >256 8 >256 ≤0.5 2 64
C2 K ABC375 64 8 16 32 >128 128 >64 >256 >256 >256 4 >256 >256 1 32
C2 K ABC716 32 8 16 >128 >128 >128 >64 >256 >256 >256 >256 16 64 2 8
C2 K BA1 64 8 16 128 >128 >128 >64 >256 >256 >256 >256 >256 ≤0.5 1 16
S7 L ABC334 64 8 32 128 >128 >128 64 256 >256 >256 >256 >256 ≤0.5 0.25 32
C1 M ABC643 64 128 128 >128 >128 >128 >64 >256 >256 >256 4 256 ≤0.5 2 64
S4 N ABC220 256 64 128 >128 >128 >128 64 256 16 >256 4 256 32 0.5 256









The array of acquired antibiotic resistance genes matched the susceptibilities 
of the isolates, e.g. high-level tetracycline resistance was observed with isolates 
possessing the tet(D) gene. Similarly, the few isolates susceptible to chloramphenicol 
were the ones lacking any phenicol resistance genes. However, the lack of acquired 
phenicol resistance genes did not translate always to susceptibility to 
chloramphenicol, suggesting alternative resistance mechanisms. The colistin 
resistance observed in one third of the isolates was not due to the presence of mobile 
colistin resistance genes and did not correlate with certain clusters. Nevertheless, 
detection of chromosomal mutations leading to colistin, to tigecycline or to 
ciprofloxacin resistance was beyond the scope of our current investigations.  
In order to investigate the carbapenemase carrying plasmids one 
representative of each subgroup defined in Table 19 was chosen for plasmid transfer 
experiments. 
All NDM-plasmids were conjugative into E. coli J53RAZ. Conjugal transfer of 
blaNDM-1 from ABC643, a strain in which the hybridization did not localize the gene 
on a plasmid, was successful, resulting in transconjugant harboring a plasmid of 
approximately 240kb size. Among the OXA-plasmids, those carrying blaOXA-48 could 
be mobilized into E. coli J53RAZ. One of the blaOXA-162 carrying plasmid was also 
conjugative. Those harboring blaOXA-232 were non-conjugative. These latter ones 
were transferred into E. coli DH5α by CaCl2 transformation. The plasmid 
incompatibility types determined by PBRT of the single plasmid containing 






Table 25: Basic characteristics of carbapenemase carrying plasmids of CRKP-14 
isolates 
SG Strain 
NDM-1 plasmid OXA plasmid 
Size Inc type C 
OXA 
allele 
size Inc type C 
A ABC252 ≥240Kb IncHI1B C OXA-232 ≈6Kb IncColKP3 NC 
B SA121 ≥240Kb IncHI1B C OXA-48 ≈60Kb IncL/M C 
C ABC261 ≥240Kb IncHI1B C OXA-162 ≈60Kb IncL/M C 
D ABC131 ≥240Kb IncHI1B C none NA NA NA 




F RH60 ≈120Kb IncFII C OXA-232 ≈6Kb IncColKP3 NC 
G DHKp6 ≈120Kb IncFII C none NA NA NA 
H ABC241 ≈120Kb IncFII C OXA-232 NL NA NA 
I MCH15 NA NA NA OXA-162 ≈60Kb IncL/M NC 
J ABC232 NA NA NA OXA-232 ≈10Kb IncColKP3 NC 
K ABC270 NA NA NA OXA-232 ≈6Kb IncColKP3 NC  
M ABC643 ≥240Kb IncHI1B C none NA NA NA 
 
C conjugative, NA not applicable, NL not localized on plasmid, NC non-conjugative 
  
To compare the CRKP-ST14 isolates of this study to international members 
of this clone we performed the cgMLST on our strains along with complete genomes 
of K. pneumoniae ST14 retrieved from GenBank: PittNDM01, KP617, and 
NUHL24835 (Figure 16). The main characteristics of these reference sequences are 
listed in Table 26. 
Table 26: Characteristics of K. pneumoniae ST14 complete genome reference 
sequences 
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Figure 16: Minimum spanning tree based on cgMLST of CRKP-ST14 (color coded 
based on the country of isolation) 
 
As it is shown in Figure 16, the reference genomes of CRKP-ST14 harboring 






Chapter 4: Discussion 
 
Although the presence of CRE has been reported repeatedly from countries of 
the Arabian Peninsula, only few studies used detailed molecular investigations to 
reveal the driving force behind the emergence of this critical type of human pathogen 
[156, 172, 194, 195, 314, 317-319, 326]. These studies documented limited clonal 
expansion as well as plasmid mediated outbreak behind the emergence of certain 
carbapenemase type producing isolates. Clonal expansion was mainly seen with K. 
pneumoniae producing NDM-1 or OXA-48-like carbapenemases [156, 317], whereas 
plasmid mediated spread explained a temporary increase of VIM-4 carbapenemase 
producing isolates in Kuwait [172]. The CRE encountered in this region produced 
mainly OXA-48 or NDM-1carbapenemases [195, 314, 317], with sporadic 
occurrence of VIM-4 [173, 326], OXA-181[319], OXA-162, OXA-232 [329], NDM-
5 [314], NDM-7 [318] and KPC-2 [157] producing isolates. Infrequently, double 
carbapenemase producing isolates were also reported [314, 317, 329]. In the early 
stage of the emergence of NDM-producing Enterobacteriaceae in the UAE, the 
phenomenon was partially attributed to the spread of a specific type of conjugative 
plasmid, IncX3 harboring the blaNDM-1 and blaSHV-12 beta-lactamases [417]. The same 
plasmid type carried blaNDM-7 in all isolates identified in the Arabian Peninsula [318], 
and blaKPC-2 in the first reported KPC-producing K. pneumoniae strains from the 
region [157]. These all suggested the prominent role of this plasmid to acquire and 
disseminate carbapenemase genes in this geographic area.  
To investigate this hypothesis, we systematically screened CRE isolated in 
the UAE, and found that the carbapenemase producer Enterobacteriaceae (CPE) 





producer CRE, which was largely due to the high proportion of IncX3 plasmid 
carrying isolates in the NDM-producing group. Transfer and complete sequencing of 
these plasmids from CPE proved that indeed all of them harbored one of the 
following carbapenemase genes: blaNDM-1, blaNDM-4, blaNDM-5, blaNDM-7, blaOXA-181 
and blaKPC-2.  
However, this observation from the UAE was not unique, as all of these 
carbapenemases have been reported to be carried on IncX3 plasmids in various 
regions of the world as shown in Table 2.  
In order to study whether the IncX3 plasmids occur in the UAE as a result of 
a local evolution, or rather as a consequence of international transfer, we compared 
the conserved regions of plasmids of the UAE to the ones reported earlier from 
various countries (Table 11) [230, 311, 318, 395, 415, 416, 427, 428, 430, 448, 449]. 
The analysis identified clades based on the carbapenemase genes carried, i.e. close 
phylogenetic relationship of IncX3 plasmids harboring blaNDM-1, blaNDM-4 and blaNDM-
7 from the UAE and from different countries of the Middle-East, Asia, Europe and 
North-America was observed. On the other hand, blaNDM-5 carrying plasmids from 
the UAE, Czech Republic, China, Hong Kong, India and South Korea formed a 
distinct clade. blaOXA-181 carrying IncX3 plasmids originating from the UAE, as well 
as from Lebanon, Germany, Denmark, Czech Republic, Switzerland, China, South 
Korea and Myanmar formed another distinct clade with a single outlier (MG228426) 
from Italy, only. The KPC-IncX3 plasmids were phylogenetically heterogeneous: 
while two blaKPC-2 harbouring plasmids from Hong Kong and from France mapped 
relatively close (JX104759 and JX461340), the backbone of the plasmid coding for 





carrying blaKPC-3 (KT362706) were distant. These data suggest that the various 
carbapenemase gene carrying IncX3 plasmids recovered in the UAE are rather the 
result of international transfer of this successful plasmid type, and not the 
consequence of local evolution.  
The sequence types of the isolates harboring IncX3 type plasmids partially 
support this notion, as OXA-181 producing E. coli ST410 harboring the 
carbapenemase on IncX3 plasmids were reported from countries of three continents: 
China, Italy, Poland and Canada [230, 450-452]. Recently it was established that this 
sequence type of E. coli is to be considered an emerging high-risk clone, too [453]. 
Similarly, E. coli ST167 harboring blaNDM-5 was present in the Czech Republic [311] 
and China  [454], and the same clone was also reported to harbor blaNDM-7 on IncX3 
plasmid from France [455] and India [456]. However, E. coli ST167 with blaOXA-181 
carrying IncX3 plasmid has not been encountered yet, although a single locus variant 
of ST167 was reported to carry this carbapenemase gene from São Tomé and 
Príncipe [457].  
On the other hand, the clonal spread of K. pneumoniae ST1318, and 
especially the five K. pneumoniae ST11 harboring blaNDM-1 demonstrates that the 
international transfer is not the only mechanism behind the emergence of this 
plasmid. Combination of the IncX3 plasmid and the K. pneumoniae ST11 clone, both 
considered to have epidemic potential [238], is especially worrisome.  
Apart from K. pneumoniae ST11, member of another high-risk K. 
pneumoniae clone was encountered, a single K. pneumoniae ST307 carrying blaNDM-
5 on an IncX3 plasmid. This finding is novel, as members of this clone have been 





blaKPC-3 and blaVIM-1, in Spain, Italy, Pakistan, South Korea [310, 449, 453, 458]  and 
even in the UAE [329], but production of NDM-5 by this clone has not been reported 
yet. Since the K. pneumoniae ST307 reported earlier from the UAE and the one 
described in this study were isolated in the same hospital, and both carried blaOXA-162 
as well [329], the possibility of local acquisition of blaNDM-5 carrying IncX3 plasmid 
cannot be excluded. 
Beyond the role of epidemic plasmids, earlier observations suggested that 
clonal dissemination of K. pneumoniae ST14 has also played a role in the emergence 
of CRE in the UAE [156, 329]. The systematic study conducted in 2015 June-2016 
June in Dubai has confirmed these early observations. The data of this study unveiled 
a large, multi-hospital dissemination of the clone, in a scenario where 39% of all 
CRE cases investigated were attributed to K. pneumoniae ST14. Although the first 
reported NDM-producing K. pneumoniae belonged to this clone, i.e. ST14 [174], and 
it has been also described from India, the United Kingdom and Sweden to carry 
blaNDM [299] or from the USA and South Korea to co-produce OXA-48-like and 
NDM carbapenemases [404, 459], to the best of our knowledge, our findings were 
the first report on the spread of carbapenemase producing K. pneumoniae ST14 clone 
on a multi-hospital scale. KPC-producing isolates were not identified in this 
collection, although the first KPC producing K. pneumoniae strains from the Arabian 
Peninsula were reported from Dubai as K. pneumoniae ST14 carrying blaKPC-2 on 
IncX3 plasmid [157]. The most common mechanism of carbapenem resistance in 
CRE of Dubai were the production of OXA-48-like and NDM carbapenemases, like 
it is common in the Arabian Peninsula [156, 194, 317]. The identification of the 





of this study; however the whole genome sequencing project discussed later shed 
light to the complexity of carbapenemases and plasmids.  
K. pneumoniae ST14 high risk clone was reported to cause neonatal 
outbreaks: in Italy K. pneumoniae ST14 producing FOX-7 AmpC beta-lactamase  
[460], in Tanzania K. pneumoniae ST14 producing CTX-M-15 ESBL occurred in 
clusters of neonatal infections, respectively [461]. Furthermore, a retrospective study 
conducted in Shanghai showed a clonal dissemination of NDM-producing K. 
pneumoniae ST14 isolates at different times in pediatric patients [462]. We have not 
observed this association with a certain age group; however, the clone was 
significantly more likely to be isolated from Emirati patients (Table 16).  
It was also notable that almost 20% of the isolates from Dubai co-produced 
NDM and OXA-48-like carbapenemases, and this feature was significantly 
associated with the K. pneumoniae ST14 clone, and only one double carbapenemase 
producing isolate belonged to a different sequence type, K. pneumoniae ST1513. 
K. pneumoniae ST14 was not only associated with double carbapenemase 
production, but also with extreme drug resistance (Table 16). Furthermore, two of the 
four pan-drug resistant isolates also belonged to this clone, with the other to being 
ST15 and ST231, respectively. 
Beyond the spread of K. pneumoniae ST14 clone, smaller clusters of K. 
pneumoniae ST147 producing either NDM (n=6) or OXA-48-like (n=4) 
carbapenemase were also encountered. This high risk clone has been reported from 





of this clone occurred in multiple hospitals [314]. In Dubai, the pan-drug resistant 
isolates belonged to different STs, as discussed above. 
This study also revealed an overall high rate of colistin resistance (31.4%) in 
carbapenem resistant K. pneumoniae (CRKP).  This rate of resistance is particularly 
alarming, as higher rate of colistin resistance in CRKP was only reported from Italy 
(43%), where the majority of colistin resistance was due to clonal spread of KPC-
producer K. pneumoniae CC258 [463]. In Dubai the picture seemed to be more 
complex: as only 59% of colistin resistant CRKP belonged to the locally prevalent 
ST14 clone, a large part (41%) was due to sporadic isolates.  No plasmid-coded 
colistin resistance gene was detected, although such mechanism has already been 
reported from human isolates in the region, even among carbapenem resistance 
strains [433]. Further investigating the chromosomal mutations leading to colistin 
resistance was beyond the scope of the study. 
A limitation of the study was that the collection did not encompass all non-
repeat isolates of the period, as we faced considerable logistic constrains in the 
submission of strains. Nevertheless, this was a problem occurring randomly, and no 
specific selection criteria were applied by the participating hospitals. The fact that the 
proportion of K. pneumoniae in the collection studied (78.6%) was practically 
identical to those among all CRE encountered during the study period (77.9%) 
suggests that the random submission of the strains had limited, if any, impact on the 
validity of our findings.  
The other drawback was the almost complete lack of epidemiological data, 
although, the fact that K. pneumoniae ST14 strains occurred in all hospitals 





seems to affect a large proportion of local hospitals both in the state, as well as in the 
private sector.  Furthermore, such data would be needed to verify and explain the 
current unexpected observation regarding the significant association of the ST14 
clone with Emirati patients, for which, currently, without access to detailed clinical 
information on the patients, we do not have a specific explanation.  
For a deeper understanding of the dynamics of CRKP-ST14 we selected 
strains of our Arabian Peninsula-wide collection, and screened them first by PFGE. 
If the PFGE pattern was ≥80% similar to known K. pneumoniae ST14, we 
considered them ST14-like. With this pre-selection, CRKP-ST14-like isolates were 
identified from Bahrain, Saudi Arabia and the UAE. As CRKP from various 
countries were not collected systematically, but for smaller scale studies only, the 
fact that the clone was not identified by us in Kuwait or Oman, does not exclude the 
possibility of its presence in those countries as well. Furthermore, the selection based 
on PFGE pattern similarity might have excluded potential CRKP-ST14 isolates with 
different PF patterns to known K. pneumoniae ST14, but for practical reasons we 
used this approach as MLST of over 700 isolates would have been very laborious. 
Even with this pre-selection criteria we found a remarkable variety in the 
carbapenemase genes, e.g. ST14-like CRKP carried blaNDM-1, blaOXA-162, blaOXA-232, 
blaKPC-2 or combinations of either blaNDM-1 and blaOXA-232, blaNDM-1 and blaOXA-162, or 
blaNDM-1 and blaOXA-48. Multi-locus sequence typing of ST14-like CRKP isolates with 
variable carbapenemase genes and PFGE patterns with <90% similarity proved that 
all 70 CRKP selected for MLST indeed belonged to ST14. This variety of 
carbapenemase gene content further confirms the earlier observations describing this 
high-risk clone as one, which is particularly fit to acquire resistance plasmids and 





ESBLs (mostly CTX-M-15, SHV-2), AmpC cephalosporinases (DHA, FOX-7 and 
CMY-2) and carbapenemases (KPC-2, KPC-3, OXA-48, OXA-181, OXA-232, 
NDM-1, NDM-5) [238, 404, 458, 459], but to the best of our knowledge our study is 
the first to detect blaOXA-162 in K. pneumoniae ST14.  
We have selected 39 CRKP-ST14 isolates for whole genome sequencing 
based on the alleles of the carbapenemase genes and the plasmid localizations of 
these genes from the 15 subgroups listed in Table 19. All of this 39 isolates were 
multi-drug or extremely drug resistant (Table 24), and harbored a remarkable array 
of acquired resistance genes coding for beta-lactam, aminoglycoside, sulfonamide, 
trimethoprim, phenicol and macrolide non-susceptibility. Tetracycline, rifampicin 
and plasmid mediated quinolone resistance genes were less uniformly harbored by 
the isolates sequenced (Table 23).  The non-carbapenemase genes did not show a 
particular association with the subgroups defined (Table 19 and Table 23). 
cgMLST of the selected CRKP-ST14 isolates grouped them into three 
clusters that differed by up to 14 out of 2358 alleles, and seven singletons. These 
clusters only showed association with the city and hospital of isolation for the 
isolates of Saudi Arabia. Clusters were not associated with particular type of 
carbapenemase or plasmid size/type either (Figure 13, Figure 14, Table 19 and Table 
22). 
Nevertheless, a clear association of clustering and harbouring KL2 or KL64 
capsular locus was demonstrated (Figure 15 and Table 22). K. pneumoniae ST14 
clone have been extensively reported and associated with serotype K2, which is one 
of the most prevalent K. pneumoniae serotype linked to hypervirulence and invasive 





pneumoniae ST14 harboring KL64. This capsular serotype was reported to be 
associated with numerous STs, including ST11, ST20, ST859, ST247, ST1711 and 
overall it was the most prevalent in Taiwan [464]. Capsular type  K64 has recently 
been associated with a fatal bacteremia caused by a hypermucoviscous blaKPC-2 
producing ST11 K. pneumoniae [464] and another case of blaNDM-1 producing 
hypermucoviscous and hypervirulent ST1764 K. pneumoniae in China [465]. 
Furthermore, it has been described in hypervirulent K. pneumoniae ST147 in the 
United Kingdom [316]. Further studies are needed to investigate whether this 
capsular switch in CRKP-ST14 from the well-known K2 type to K64 increases or 
changes virulence, or simply helps the pathogen to avoid immune recognition, and 
helps the dissemination of this clone, as was hypothesized in case of  ST11 and 
CC258 with capsular variations [238].  
As we pre-selected the strains for whole genome sequencing, statistical 
analysis of association with capsular types and the type of infections would have 
been skewed, nevertheless in the pool of strains subjected to whole genome 
sequencing the proportion of bloodstream and respiratory isolates was higher in the 
group of strains harboring KL64 capsular locus. 
Irrespective of a potential change in virulence caused by the capsular switch, 
the phenomenon certainly has an implication if the phage derived capsule-targeting 
depolymerase therapy will be considered as an alternative or additional therapy to 
antibiotics [466]. 
It was interesting to note that CRKP-ST14-K2 and CRKP-ST14-K64 isolates 
overlapped both in time and in terms of the hospitals they were isolated from.  





governmental hospitals of Dubai (RH and DH), a tertiary care hospital in Al Ain 
(TH) and two other tertiary care hospitals in Abu Dhabi (SKMC, ZMH), as well 
(Tables 20 and 22). 
Although we tested isolates from 5 different locations from Saudi Arabia 
(data not shown), we have encountered strains with PFGE patterns ≥80% similarity 
to known K. pneumoniae ST14 isolated in a single Saudi hospital only, which formed 
a distinct group and were far more similar to each other, than the CRKP-ST14 of the 
UAE. This suggests that the clone has only recently been arisen in that country, 
supported also by the fact that all these isolates were from 2015. 
Comparing our isolates to the internationally encountered CRKP-ST14 
(Table 26) revealed that isolates in Cluster 1 (CRKP-ST14 from the UAE) were 
highly related to both of the NDM-1 and OXA-232 producing K. pneumoniae ST14 
reference genome, to the extent that the Korean [459] even fitted into the cluster with 
8 locus differences only. The CRKP-ST14 from the USA, originally considered to be 
imported from India [404], was also very close (18 locus different of the 2358) by 
cgMLST to K pneumoniae ABC127 isolated in 2011 in Sharjah (Figure 16).  The 
NDM-5 producing ST14 isolate from China [467] exhibited more distant cgMLST 
profile, with being closest (179 allele difference) to KPC-2 producing isolate 
ABC220 (Figure 16). Interestingly, the carbapenemase genes; blaNDM-5 in 
NUHL24835 [467] and blaKPC-2 in ABC220 [157] were both located on IncX3 
plasmids. All three reference genomes were of CRKP-ST14 with capsular type K2, 
suggesting that the capsular switch encountered in the UAE was a recent 





Our investigations have several limitations. Unfortunately, our data could not 
be aligned with epidemiological observations, indeed, lack of certain correlates such 
as travel information, dietary habits, clinical presentations and their associated 
outcomes have impeded our understanding of the dissemination of CREs in the study 
setting. The various sub-clones of K. pneumoniae ST14 strains occurring in 12 
hospitals of the UAE highlight the need for such data. 
A further shortcoming of our studies on CRKP-ST14 was that we have not 
tested the level of susceptibility to disinfectants, which may explain the sustained 
presence of this clone in the hospitals [243]. Nevertheless, the lack of generally 
accepted breakpoints for biocide resistance makes the interpretation of such tests 
difficult. 
Furthermore, assessing the molecular mechanisms other than the presence of 
acquired resistance genes (e.g. chromosomal mutations, porin-loss, and efflux pump 
hyper-expression) causing resistance to colistin, tigecycline, chloramphenicol and 








Chapter 5: Conclusion 
 
Systematic screening of 334 carbapenem resistant Enterobacteriaceae for 
IncX3 incompatibility type plasmids, i.e. for a type of plasmid implicated in the early 
emergence of CRE in the United Arab Emirates, revealed 30 carbapenemase carrying 
IncX3 plasmids, i.e. 9.6% of CRE carried carbapenemase on this specific type of 
plasmid. 
The CRE strains carrying carbapenemase genes on IncX3 plasmids were 
diverse; they belonged to 16 different sequence types of five species of 
Enterobacteriaceae. Some of these strains belonged to high-risk epidemic clones of 
Enterobacteriaceae, e.g. K. pneumoniae ST11, K. pneumoniae ST14, and E. coli 
ST410. 
The carbapenamase genes carried on IncX3 plasmids were also diverse: 
blaNDM-1, blaNDM-4, blaNDM-5, blaNDM-7, blaOXA-181 and blaKPC-2 were encountered. 
Establishing the complete sequence of 21 IncX3 plasmids of the UAE 
harboring various carbapenemase genes showed high level of similarity in regions 
coding for plasmid replication, partitioning and mobilization, suggestive of a 
potential local evolution of these plasmid acquiring various genetic loads, i.e. 
resistance genes. 
Nonetheless, phylogenetic analysis of the conserved regions of local IncX3 
plasmids and of those described globally clustered them according to the 
carbapenemase genes carried, suggesting that they do not evolve locally, rather, were 





Furthermore, investigating the molecular epidemiology of carbapenem-
resistant Enterobacteriaceae (CRE) isolated over a year-long period in major 
hospitals of Dubai revealed an alarmingly high rate (33%) of extremely drug 
resistant, or colistin resistant (27%) isolates.  
Thirty-nine percent of this collection belonged to a K. pneumoniae ST14 
clone, members of which were identified in all participating hospitals. 
This clone showed significant association with double carbapenemase 
production, with extreme drug resistance, and with being isolated from Emirati 
patients.  
To gain a deeper insight into the molecular features of this clone, 39 CRKP-
ST14 selected from five cities of the UAE, from Bahrain and from Saudi Arabia 
were subjected to whole genome sequencing (WGS), and their resistome, virulome 
and core genome MLST was assessed.  
One of the isolates selected for WGS did not produce a carbapenemase, but 
38 of them carried either single carbapenemases: blaNDM-1, blaOXA-162, blaOXA-232, 
blaKPC-2, or a combinations of blaNDM-1 and blaOXA-232, blaNDM-1 and blaOXA-162, or 
blaNDM-1 and blaOXA-48. Although K. pneumoniae ST14 has been known to carry a 
variety of carbapenemases, our study demonstrated the first time the production of 
OXA-162 by K. pneumoniae ST14. 
blaNDM-1 was located on conjugative an IncHI1b or on an IncFII type 
plasmids, blaOXA-162 and blaOXA-48 on IncL/M type plasmid some of which were self-
transmissible, whereas blaOXA-232 was located on non-conjugative plasmids of 





cgMLST revealed three clusters of 16 isolates from five UAE cities (C1), 11 
isolates from three UAE cities and Bahrain (C2) and 5 isolates from Saudi Arabia 
(C3), respectively, and seven singletons. Resistance gene profile and carbapenemase 
carrying plasmid types were variable in both C1 and C2 clusters, while C3 clustering 
the isolates from Saudi Arabia was more uniform. 
Although, K. pneumoniae ST14 is generally believed to be associated with 
capsular serotype K2, we found that isolates of cgMLST cluster C2, and two closely 
related singletons, carried genes of capsular locus KL64, a capsular type, which, to 
the best of our knowledge, has never been described earlier in this clone. 
The capsular switch within the clone not only further emphasises its genetic 
flexibility, but may directly promote its transmission by evading immune 
recognition. 
Altogether, our data showed that the emergence of CRE in the United Arab 
Emirates is a complex phenomenon of likely international transfer of successful 
plasmids and clones, combined with countrywide clonal dissemination of a 








Chapter 6: Recommendation 
 
Our data demonstrating a nationwide spread of a high-risk Klebsiella 
pneumoniae clone highlights the necessity of surveillance and epidemiological 
investigations to monitor the antibiotic resistance situation countrywide in the United 
Arab Emirates.  
The continuous surveillance should be supported by the establishment of a 
national antimicrobial reference laboratory able to conduct confirmatory tests and 
molecular epidemiological investigations.  
To control the clonal spread occurring locally, as well as, to monitor the 
internationally transferred  CRE,  heightened infection control measures including 
active screening for CRE is needed in all hospitals of the UAE.  
Furthermore, as the non-judicious use of antibiotics facilitates the spread of 
drug-resistant organisms by increasing the selection pressure, antibiotic stewardship 
programs in the inpatient care should be extended to the outpatient healthcare 
settings, along with enforced reduction of antibiotics consumption in the agriculture, 
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Part 1 Carbapenemase carrying IncX3 plasmids in the United Arab Emirates 
Illustrating the plasmid profile similarities between host strains  
 
 












II.Plasmid profile analysis of ABC280 and ABC286 
 
 











































Part 2 In order to localize the carbapenemase genes; Hybridization with NDM-probe, 
OXA-48-like probe were performed for the 170 ST14-looking like isolates as shown 
in the following figures.  
 




































































II. OXA-48-like hybridization 
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